COMPREHENSIVE CARE CORP (Form: 10-Q, Received: 05/15/2009 17:28:01)

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2009

Commission File Number 1-9927

COMPREHENSIVE CARE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

95-2594724

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

3405 W. Dr. Martin Luther King Jr. Blvd, Suite 101, Tampa, FL 33607

(Address of principal executive offices and zip code)

(813) 288-4808

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of May 13, 2009, there were 24,027,218 shares of registrant’s common stock, $0.01 par value, outstanding.

T ABLE OF C ONTENTS


		PAGE
PART I – FINANCIAL INFORMATION

I TEM 1 — C ONSOLIDATED F INANCIAL S TATEMENTS

Consolidated Balance Sheets as of March 31, 2009 (unaudited), December 31, 2008 and December 31, 2008 (Predecessor)		3

Consolidated Statements of Operations for the three months ended March 31, 2009 (unaudited), twenty days ended January 20, 2009 (Predecessor) (unaudited) and three months ended March 31, 2008 (Predecessor) (unaudited)		4

Consolidated Statements of Cash Flows for the three months ended March 31, 2009 (unaudited), twenty days ended January 20, 2009 (Predecessor) (unaudited) and three months ended March 31, 2008 (Predecessor) (unaudited)		5

Notes to Consolidated Financial Statements		6-19

I TEM 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations		19-27

I TEM 3 — Quantitative and Qualitative Disclosures About Market Risk		27

I TEM 4 — Controls and Procedures		27

PART II – OTHER INFORMATION

I TEM 1 — L EGAL P ROCEEDINGS		28

I TEM 1A — R ISK F ACTORS		28

I TEM 2 — U NREGISTERED S ALES OF E QUITY S ECURITIES AND U SE OF P ROCEEDS		28

I TEM 4 — S UBMISSION OF M ATTERS TO A V OTE OF S ECURITY H OLDERS		29

I TEM 5 — O THER I NFORMATION		29

I TEM 6 — E XHIBITS		31

S IGNATURES		32

C ERTIFICATIONS

-2-

PART I – FINANCIAL INFORMATION

Item 1.

Consolidated Financial Statements

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)


	March 31, 2009			December 31, 2008			(Predecessor) December 31, 2008
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	1,011		$	503		$	1,136
Accounts receivable		48			—			1,581
Other current assets		463			—			336

Total current assets		1,522			503			3,053

Property and equipment, net		218			—			235
Unallocated assets, net of amortization of $123		13,761			—			—
Goodwill		25			25			991
Other assets		300			—			326

Total assets		15,826			528			4,605


LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued liabilities		2,200			149			1,953
Accrued claims payable		4,560			—			6,791
Accrued pharmacy payable		92			—			—
Income taxes payable		23			—			19

Total current liabilities		6,875			149			8,763


Long-term liabilities:
Long-term debt		2,444			—			2,444
Other liabilities		2,575			—			2,589

Total long-term liabilities		5,019			—			5,033

Total liabilities		11,894			149			13,796


Stockholders’ equity (deficit):
Preferred stock, $50.00 par value; authorized shares: 7,400, none, and 4,340, respectively; none issued		—			—			—
Preferred stock, Series A, $50.00 par value; authorized shares: none, none, and 14,400 respectively; issued and outstanding: none, none, and 14,400, respectively		—			—			720
Preferred stock, Series B-1, $50.00 par value; authorized shares: 1,675, none and none respectively; issued and outstanding: 1,675, none, and none, respectively		84			—			—
Preferred stock, Series B-2, $50.00 par value; authorized shares: 2,665, none and none respectively; issued and outstanding: 2,665, none and none, respectively		133			—			—
Preferred stock, Series D, $50.00 par value; authorized shares: 7,000, none and none, respectively; none issued		—			—			—
Common stock, $0.01 par value; authorized 30,000,000 shares; issued and outstanding 23,926,218, 1,760,000, and 8,327,766 respectively		239			18			83
Common stock subscribed		—			4			—
Additional paid-in capital		8,618			1,516			57,919
Common stock subscriptions receivable		—			(1,000	)		—
Accumulated deficit		(5,123	)		(159	)		(67,918	)

Total stockholders’ equity (deficit)		3,951			379			(9,196	)

Non-controlling interest		(19	)		—			5

Total equity (deficit)		3,932			379			(9,191	)

Total liabilities and equity	$	15,826		$	528		$	4,605

See accompanying notes to condensed consolidated financial statements.

-3-

C ONSOLIDATED S TATEMENTS OF O PERATIONS

(Unaudited)

(Amounts in thousands, except per share amounts)


				(Predecessor)
	Three Months Ended March 31, 2009			January 1 To January 20, 2009			Three Months Ended March 31, 2008
Revenues:
Managed care revenues	$	3,401		$	710		$	9,333
Other revenues		4			—			—

Total revenues		3,405			710			9,333

Costs of services and sales:
Cost of care		2,823			703			9,739
Other costs of services and sales		1			—			—

Total costs of services and sales		2,824			703			9,739


Gross margin		581			7			(406	)

Expenses:
General and administrative expenses		1,136			142			913
Recovery of doubtful accounts		(2	)		(2	)		—
Depreciation and amortization		148			5			40

Total operating expenses		1,282			145			953
Merger transaction costs		589			480			—
Equity based expenses		4,361			91			35

Total expenses		6,232			716			988


Operating loss		(5,651	)		(709	)		(1,394	)

Other income (expense):
Interest income		—			—			12
Interest expense		(50	)		(11	)		(47	)

Loss before income taxes		(5,701	)		(720	)		(1,429	)
Income tax expense		4			1			3

Net loss before pre-acquisition loss		(5,705	)		(721	)		(1,432	)
Add back pre-acquisition loss		721			—			—

Net loss after pre-acquisition adjustments		(4,984	)		(721	)		(1,432	)
Add back: Net loss attributable to non-controlling interest		20			4			—

Net loss attributable to stockholders	$	(4,964	)	$	(717	)	$	(1,432	)


Basic and diluted loss per share	$	(0.22	)	$	(0.09	)	$	(0.19	)


Weighted average common shares outstanding:

Basic		22,966			8,328			7,727


Diluted		22,966			8,328			7,727


Dilutive common shares without respect to anti-dilutive effect		33,081			13,745			12,092

See accompanying notes to condensed consolidated financial statements.

-4-

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(Amounts in thousands)


				(Predecessor)
	Three Months Ended March 31, 2009			January 1 To January 20, 2009			Three Months Ended March 31, 2008
Cash flows from operating activities:
Net loss	$	(4,964	)	$	(717	)	$	(1,432	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		143			5			40
Non-controlling interest		(20	)		(4	)		—
Equity based expenses		4,270			91			35

Changes in assets and liabilities:
Accounts receivable		568			965			(599	)
Other current assets and other non-current assets		(120	)		13			(221	)
Accounts payable and accrued liabilities		(43	)		141			(322	)
Accrued claims payable		(1,077	)		(1,154	)		88
Accrued pharmacy payable		48			44			—
Income taxes payable		4			—			3
Other liabilities		(2	)		3			—

Net cash used in operating activities		(1,193	)		(613	)		(2,408	)


Cash flows from investing activities:
Cash paid for the acquisition of a business, net of cash acquired		(978	)		—			—
Payment received on notes receivable		4			2			7
Additions to property and equipment, net		(6	)		—			(22	)

Net cash (used in) provided by investing activities		(980	)		2			(15	)


Cash flows from financing activities:
Net proceeds from the issuance of common stock		2,695			—			32
Repayment of debt		(14	)		(3	)		(13	)

Net cash provided by (used in) financing activities		2,681			(3	)		19

Net increase (decrease) in cash and cash equivalents		508			(614	)		(2,404	)
Cash and cash equivalents at beginning of period		503			1,136			6,313

Cash and cash equivalents at end of period	$	1,011		$	522		$	3,909


Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest		7			1			4

Income taxes		—			—			—

Non-cash operating, financing and investing activities:
Property acquired under capital leases		—			—			6

See accompanying notes to condensed consolidated financial statements.

-5-

N OTE 1 – D ESCRIPTION OF THE C OMPANY ’ S B USINESS AND B ASIS OF P RESENTATION

The accompanying unaudited interim condensed consolidated financial statements for Comprehensive Care Corporation (referred to herein as the “Company,” “CompCare,” “we,” “us” or “our”) and its subsidiaries have been prepared in accordance with the Securities and Exchange Commission (“SEC”) rules for interim financial information and do not include all information and notes required for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the consolidated financial statements and the notes thereto in our most recent report on Form 10-K.

Our consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Comprehensive Behavioral Care, Inc. (“CBC”) and Core Corporate Consulting Group, Inc. (“Core”), each with their respective subsidiaries. Through CBC, we provide managed care services in the behavioral health and psychiatric fields. We manage the delivery of a continuum of psychiatric and substance abuse services to commercial, Medicare, Medicaid and Children’s Health Insurance Program (“CHIP”) members on behalf of employers, health plans, government organizations, third-party claims administrators, and commercial and other group purchasers of behavioral healthcare services. We also provide prior and concurrent authorization for physician-prescribed psychotropic medications for a major Medicaid health maintenance organization (“HMO”) in Michigan, and behavioral pharmaceutical management services for a Puerto Rico health plan. The managed care operations include administrative service agreements, fee-for-service agreements, and capitation contracts. The customer base for our services includes both private and governmental entities. Our services are provided primarily by unrelated vendors on a subcontract basis. Through Core we market a variety of health related products, insurance, and discount plans to targeted markets such as the uninsured, the underinsured, and underserved ethnic groups.

On January 20, 2009, CompCare acquired Core, a privately held company, in exchange for CompCare common and convertible preferred stock. As a result of the merger, the former Core shareholders as a collective group obtained voting control of CompCare. Consequently, the transaction was accounted for as a reverse acquisition with Core designated as the accounting acquirer and CompCare as the predecessor. The combined entity has elected to retain the Comprehensive Care Corporation name and status as a SEC registrant.

As a result of Core being treated as the accounting acquirer, the historical financial statements of the combined entity were restated to be those of Core. Therefore, the consolidated balance sheet as of December 31, 2008 presented herein includes only the accounts of Core at historical carrying amounts. In contrast, the unaudited, consolidated balance sheet as of March 31, 2009 is a combination of Core and Compcare accounts. The capital structure (common and preferred stock) of CompCare as the registrant was retained and the accumulated deficit of Core at the time of the merger was carried forward as the beginning retained deficit balance for the combined company.

For comparative purposes, the predecessor company’s financial activity for the quarter ended March 31, 2008 is provided in the consolidated statement of operations and consolidated statement of cash flows presented herein. To facilitate comparison, the pre-acquisition results for CompCare for the period January 1 to January 20, 2009 are shown in the consolidated statements of operations and consolidated statements of cash flows. Earnings per share for periods prior to the merger did not require restatement because CompCare common and convertible preferred stock (on an as-converted basis) were exchanged on a one-for-one basis for Core common stock.

N OTE 2 – S UMMARY OF S IGNIFICANT A CCOUNTING P OLICIES

Revenue Recognition

Our managed care activities are performed under the terms of agreements with health maintenance organizations, preferred provider organizations, and other health plans or payers to provide contracted behavioral healthcare services to subscribing participants. Revenue under a substantial portion of these agreements is earned monthly based on the number of qualified participants regardless of services actually provided (generally referred to as capitation arrangements). The information regarding qualified participants is supplied by our clients and we review member eligibility records and other reported information to verify its accuracy to determine the amount of

-6-

revenue to be recognized. Such agreements accounted for 83.6%, or $2.8 million, and 97.4%, or $9.1 million, of revenue for the three months ended March 31, 2009 and 2008. The remaining balance of our revenues is earned on a fee-for-service basis and is recognized as services are rendered.

Healthcare Expense Recognition

Healthcare operating expense is recognized in the period in which an eligible member actually receives services and includes an estimate of the cost of behavioral health services that have been incurred but not yet reported. See “Accrued Claims Payable” for a discussion of claims incurred but not yet reported. We contract with various healthcare providers including hospitals, physician groups and other licensed behavioral healthcare professionals either on a discounted fee-for-service or a per-case basis. We determine that a member has received services when we receive a claim within the contracted timeframe with all required billing elements correctly completed by the service provider. We then determine whether the member is eligible to receive such services, the service provided is medically necessary and is covered by the benefit plan’s certificate of coverage, and the service is authorized by one of our employees. If all of these requirements are met, the claim is entered into our claims system for payment.

Unallocated Assets

Unallocated assets on our balance sheet as of March 31, 2009 represents the excess of the implied purchase price of CompCare over the net tangible assets acquired, less estimated amortization recorded during the quarter ended March 31, 2009. We are in the process of obtaining fair market values for CompCare’s identifiable intangible assets, such as its customer contracts, NCQA accreditation and provider networks. Upon completion of our valuation analysis, we will record the identifiable intangible assets at the appropriate amounts and assign the remaining excess, if any, to goodwill. An estimate for amortization has been made based on an estimated value for amortizable intangible assets of $2.0 million.

Goodwill

Goodwill represents the cost in excess of the fair value of net assets acquired in purchase transactions. Pursuant to SFAS No. 142, “Goodwill and Other Intangible Assets,” goodwill is not amortized but is periodically evaluated for impairment to carrying amount, with decreases in carrying amount recognized immediately. We review goodwill for impairment annually, or more frequently if changes in circumstances or the occurrence of events suggest impairment exists. The tests for impairment of goodwill require us to make estimates about fair value, which are based on discounted projected future cash flows and the quoted market price of our common stock.

Accrued Claims Payable

The accrued claims payable liability represents the estimated ultimate net amounts owed for all behavioral healthcare services provided through the respective balance sheet dates, including estimated amounts for claims incurred but not yet reported (IBNR) to the Company. The unpaid claims liability is estimated using an actuarial paid completion factor methodology and other statistical analyses and is continually reviewed and adjusted, if necessary, to reflect any change in the estimated liability. These estimates are subject to the effects of trends in utilization and other factors. However, actual claims incurred could differ from the estimated claims payable amount reported. Although considerable variability is inherent in such estimates, management believes that the unpaid claims liability is adequate.

Premium Deficiencies

We accrue losses under our contracts when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. We perform this loss accrual analysis on a specific contract basis taking into consideration such factors as future contractual revenue, projected future healthcare and maintenance costs, and each contract’s specific terms related to future revenue increases as compared to expected increases in healthcare costs. The projected future healthcare and maintenance costs are estimated based on historical trends and our estimate of future cost increases.

-7-

At any time prior to the end of a contract or contract renewal, if a contract is not meeting its financial goals, we generally have the ability to cancel the contract with 60 to 90 days’ written notice. Prior to cancellation, we will submit a request for a rate increase accompanied by supporting utilization data. Although our clients have historically been generally receptive to such requests, no assurance can be given that such requests will be fulfilled in the future in our favor. If a rate increase is not granted, we have the ability, in most cases, to terminate the contract and limit our risk to a short-term period.

On a quarterly basis, we perform a review of our portfolio of contracts for the purpose of identifying loss contracts (as defined in the American Institute of Certified Public Accountants Audit and Accounting Guide – Health Care Organizations) and developing a contract loss reserve, if applicable, for succeeding periods. During the three months ended March 31, 2009, our review did not identify any contracts where it was probable that a loss had been incurred and for which a loss could reasonably be estimated.

Fair Value Measurements

Statement of Financial Accounting Standard (“SFAS”) No. 157, “Fair Value Measurements,” defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. During the three months ended March 31, 2009, we had no assets or liabilities required to be measured at fair value on a recurring basis. Therefore, SFAS No. 157 did not impact our financial position or results of operations.

SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities” provides that companies may elect to measure many financial instruments and certain other items at fair value on a contract-by-contract basis, with changes in fair value recognized in earnings each reporting period. The election, called the “fair value option,” will enable some companies to reduce the variability in reported earnings caused by measuring related assets and liabilities differently. We chose not to measure at fair value our eligible financial assets and liabilities existing at March 31, 2009. Consequently, SFAS No. 159 has had no impact on our consolidated financial statements.

Income Taxes

Under the asset and liability method of SFAS No. 109, “Accounting for Income Taxes,” deferred tax assets and liabilities are recognized for the future tax consequences attributable to net operating loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under SFAS No. 109, the effect of a change in tax rates on deferred tax assets or liabilities is recognized in the consolidated statements of operations in the period that included the enactment. A valuation allowance is established for deferred tax assets unless their realization is considered more likely than not.

The purchase by Core of Hythiam’s ownership interest on January 20, 2009 resulted in a change in control of the Company. As a result, any losses incurred prior to January 20, 2009 are subject to a limitation, which approximates $361,000 per year. Any unused portion of such limitation can be carried forward to the following year. We may be subject to further limitation in the event that we issue or agree to issue substantial amounts of additional equity.

In June 2006, the FASB issued Interpretation No. 48 (“FIN 48”), “Accounting for Uncertainty in Income Taxes,” which clarifies the accounting for uncertainty in income taxes. FIN 48 requires that companies recognize in the consolidated financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods and disclosure. The provisions of FIN 48 are effective for fiscal years beginning after December 15, 2006. Our adoption of FIN 48 had no impact on our consolidated financial statements.

Stock Ownership Plans

We grant stock options to our employees and non-employee directors (“grantees”) allowing grantees to purchase our common stock pursuant to shareholder-approved stock option plans. We currently have two active

-8-

incentive plans, the 1995 Incentive Plan and the 2002 Incentive Plan (collectively, the “Plans”), that provide for the granting of stock options, stock appreciation rights, limited stock appreciation rights, restricted preferred stock, and common stock grants to eligible employees and consultants. Grants issued under the Plans may qualify as incentive stock options (“ISOs”) under Section 422A of the Internal Revenue Code. Options for ISOs may be granted for terms of up to ten years. Vesting generally occurs after six months for one-half of the options and after 12 months for the remaining options. The exercise price for ISOs must equal or exceed the fair market value of the shares on the date of grant. The Plans also provide for the full vesting of all outstanding options under certain change of control events. The maximum number of shares authorized for issuance is 1,000,000 under the 2002 Incentive Plan and 1,000,000 under the 1995 Incentive Plan. As of March 31, 2009, under the 2002 Incentive Plan, there were 375,000 options available for grant and 585,000 options were outstanding and exercisable. Additionally, as of March 31, 2009, under the 1995 Incentive Plan, there were 182,500 options outstanding and exercisable. There are no further options available for grant under the 1995 Incentive Plan.

Under our Non-employee Directors’ Stock Option Plan, we are authorized to issue 1,000,000 shares pursuant to non-qualified stock options to our non-employee directors. Each non-qualified stock option is exercisable at a price equal to the average of the closing bid and asked prices of the common stock in the over-the-counter market for the most recent preceding day there was a sale of the stock prior to the grant date. Grants of options vest in accordance with vesting schedules established by our Board of Director’s Compensation and Stock Option Committee. Upon joining the Board, directors receive an initial grant of 25,000 options. Annually, directors are granted 15,000 options on the date of the Company’s annual meeting. As of March 31, 2009, under the directors’ plan, there were 676,668 shares available for option grants and 225,000 options outstanding, of which 125,000 options were exercisable.

A summary of activity for the period January 1 to March 31, 2009 is as follows:


Options	Shares		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2009	847,500		$	0.88	6.34 years
Granted	50,000		$	0.52	9.79 years
Exercised	—			—
Forfeited or expired	—			—

Outstanding at January 20, 2009	897,500		$	0.86	6.49 years

Granted	100,000		$	0.56	9.73 years
Exercised	—			—
Forfeited or expired	(5,000	)	$	0.81

Outstanding at March 31, 2009	992,500		$	0.83	6.66 years	—

Exercisable at March 31, 2009	892,500		$	0.86	6.31 years	—

The following table summarizes information about options granted, exercised, and vested for the three months ended March 31, 2009 and 2008.


	January 1 to March 31, 2009	January 1 to March 31, 2008
Options granted	150,000	185,000
Weighted-average grant-date fair value ($)	0.51	0.52

Options exercised	—	125,000
Total intrinsic value of exercised options ($)	—	50,080

Fair value of vested options ($)	139,270	47,367

-9-

We recognized approximately $91,000 of stock option expense due to the vesting of stock options as a result of the change in control of the Company resulting from the merger on January 20, 2009.

A total of 150,000 options were granted to employees and directors during the period January 1 to March 31, 2009. At March 31, 2009, unrecognized expense related to unvested stock options totals approximately $48,000, which we expect to recognize over 4.81 years.

The following table lists the assumptions utilized in applying the Black-Scholes valuation model. We use historical data and management judgment to estimate the expected term of the option. Expected volatility is based on the historical volatility of our traded stock. We have not declared dividends in the past nor do we expect to do so in the near future and as such we assume no expected dividend. The risk-free rate is based on the U.S. Treasury yield curve with the same expected term as that of the option at the time of grant.


	J ANUARY 1 TO M ARCH 31, 2009		J ANUARY 1 TO M ARCH 31, 2008
Volatility factor of the expected market price of the Company’s common stock	225	%	125	%
Expected life (in years) of the options	5		5-6
Risk-free interest rate	1.6	%	2.59% - 3.24	%
Dividend yield	0	%	0	%

Warrants

We periodically issue warrants to purchase common and preferred stock for the services of consultants, employees and non-employee directors. On March 31, 2009, we issued warrants to purchase up to 190 shares of the Company’s Series D Preferred Stock, par value $50.00 per share, to members of the Board of Directors and certain members of management as an equity incentive to further align the interests of the directors and members of management with those of the Company’s stockholders. We recognized approximately $4.1 million of expense related to these warrants. Each warrant to purchase shares of Series D Preferred Stock may be exercised at any time between its issuance and March 31, 2012 at an exercise price of $25,000 per share of Series D Preferred Stock. If after September 30, 2009, the market value of a share of Series D Preferred Stock exceeds the exercise price for a share of Series D Preferred Stock, then the holder may exercise the warrant by a cashless exercise and receive the number of shares of Series D Preferred Stock representing the net value of the warrant and forfeiting the appropriate number of warrants. The market value of a share of Series D Preferred Stock is equal to the product of (a) the per share market price of the Company’s common stock multiplied by (b) the number of shares of the Company’s common stock into which a share of Series D Preferred Stock is then convertible.

The number of shares of Series D Preferred Stock for which a warrant is exercisable is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting the Series D Preferred Stock. In the event of a change of control (as defined in the warrants) of the Company, the holder has the right to require us to redeem the warrant in exchange for an amount equal to the value of the warrant determined using the Black-Scholes pricing model.

Each holder of Series D Preferred Shares is entitled to notice of any stockholders’ meeting and to vote on any matters on which the Company’s common stock may be voted. Each Series D Preferred Share is entitled to the number of votes that the holder of 500,000 shares of common stock would be entitled to by virtue of holding such shares of common stock. Unless otherwise required by law, holders of Series D Preferred Shares will vote together with holders of common stock as a single class on all matters submitted to a vote of the Company’s stockholders.

Each share of Series D Preferred Stock acquired through exercise of a warrant is convertible into 100,000 shares of common stock at any time. For the presentation below, warrants to purchase Series D Preferred Stock are stated in common shares, as if the warrant was exercised and the resulting Series D Preferred Stock was converted. The exercise price of the warrant has been similarly adjusted to an as converted common stock equivalent. A summary of activity from the period January 1 to March 31, 2009 is as follows:


Warrants	Shares	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at January 1, 2009	306,000	$	1.25	1.15 years
Granted	—		—
Exercised	—		—
Forfeited or expired	—		—

Outstanding at January 20, 2009	306,000	$	1.25	1.09 years

Granted	19,000,000	$	0.25	3.00 years
Exercised	—		—
Forfeited or expired	—		—

Outstanding at March 31, 2009	19,306,000	$	0.27	2.97 years	—

Exercisable at March 31, 2009	19,306,000	$	0.27	2.97 years	—

-10-

The following table summarizes information about warrants granted, exercised and vested for the three months ended March 31, 2009 and 2008.


	January 1 to March 31, 2009	January 1 to March 31, 2008
Warrants granted	19,000,000	—
Weighted-average grant-date fair value ($)	0.2181	—

Warrants exercised	—	—
Total intrinsic value of exercised warrants ($)	—	—

Fair value of vested warrants ($)	4,143,900	—

Valuation using the Black-Scholes pricing model was based on the following information:


	January 1 to March 31, 2009		January 1 to March 31, 2008
Volatility factor of the expected market price of the Company’s common stock	175	%	—
Expected life (in years) of the warrants	3		—
Risk-free interest rate	1.15	%	—
Dividend yield	0	%	—

We recognized approximately $1.6 million of tax benefits attributable to equity-based expense recorded for stock options and warrants during the period January 1 to March 31, 2009. This benefit was fully offset by a valuation allowance of the same amount due to the likelihood of future realization.

Per Share Data

In calculating basic loss per share, net loss is divided by the weighted average number of common shares outstanding for the period. For the periods presented, diluted loss per share is equivalent to basic loss per share. The following table sets forth the computation of basic and diluted loss per share in accordance with SFAS No. 128, “Earnings Per Share” (amounts in thousands, except per share data):


	Three Months Ended March 31, 2009			Three Months Ended March 31, 2008
Numerator:
Net loss	$	(4,964	)	$	(1,432	)
Denominator:
Weighted average shares – basic		22,966			7,727
Effect of dilutive securities:
Employee stock options		—			—
Warrants		—			—

Weighted average shares – diluted		22,966			7,727


Loss per share – basic and diluted	$	(0.22	)	$	(0.19	)

-11-

Capitalization Table

As of March 31, 2009


Common Stock (Authorized 30 million shares)	Issued	Reserved	Total
Common Stock issued and outstanding	23,926,218		23,926,218
Reserved for convertible debentures ^(a)		22,544	22,544
Reserved for convertible promissory note ^(b)		800,000	800,000
Reserved for outstanding stock options ^(c)		992,500	992,500
Reserved for outstanding warrants ^(d)		306,000	306,000
Reserved for future issuance under stock option plans		1,051,668	1,051,668


Total shares issued or reserved for issuance	23,926,218	3,172,712	27,098,930	(h)


Preferred Stock (Authorized 18,740 shares)	Issued	Reserved	Total
Series B1 convertible preferred stock ^(e)	1,675		1,675
Series B2 convertible preferred stock ^(f)	2,665		2,665
Reserved for warrants for Series D Convertible Preferred Stock ^(g)		190	190

Total Preferred Stock issued or reserved for issuance	4,340	190	4,530

(a)	The debentures are convertible into 22,544 shares of common stock at a conversion price of $99.54 per share.

(b)	A Promissory Note in the amount of $200,000 is convertible into 800,000 shares of common stock at a conversion price of $0.25 per common share.

(c)	Options to purchase common stock of the Company have been issued to employees and non-employee Board of Director members with exercise prices ranging from $0.25 to $2.16, with an average price of $0.86.

(d)	Warrants to purchase common stock of the Company have been issued to certain individuals or vendors in exchange for consulting services. All such warrants were issued in lieu of cash compensation and have a five-year term with an exercise price of $1.25.

(e)	The Series B1 Convertible Preferred Stock is convertible into 14,400 shares of Series C Convertible Preferred stock which in turn is convertible into 4,554,379 common shares. This class controls five out of the nine Board seats.

(f)	The Series B2 Convertible Preferred Stock is convertible directly into 7,246,871 common shares.

(g)

On March 31, 2009, the Board of Directors and senior management were issued warrants to purchase an aggregate of 190 shares of Series D Preferred Stock, which convert into 19,000,000 shares of common stock at a strike price of $25,000 per share (equal to $0.25 per common share). Each Preference D share is entitled to 500,000 votes per share in a stockholder vote.

-12-

(h)

Fully diluted shares is 57,900,180, assuming that all Preference B-1, B-2 and D shares are converted into common shares. At the conversion of B-1 and D, Series B-1 rights to elect five board members and Series D rights to five votes per share will cease. The Series B-1 and Series B-2 Preferred stock cannot be converted and the warrants to purchase Series D Preferred shares cannot be exercised until after the Company effects an increase in its authorized capital.

F AIR V ALUE OF F INANCIAL I NSTRUMENTS

FASB Statement No. 107, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of fair value information about financial instruments for which it is practical to estimate that value.

For cash and cash equivalents, restricted cash, and the note receivable, the carrying amount approximates fair value. Our financial assets and liabilities other than cash are not traded in an open market and therefore require us to estimate their fair value. Pursuant to the disclosure requirements prescribed by FAS 107, we use a present value technique, which is a type of income approach, to measure the fair value of these financial instruments. The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts and fair values of our financial instruments at March 31, 2009 and December 31, 2008 are as follows:


	March 31, 2009			December 31, 2008
	Carrying Amount		Fair Value	Carrying Amount	Fair Value
	(Amounts in thousands)
Assets
Cash and cash equivalents	$	1,011	1,011	503	503
Restricted cash		1	1	—	—
Note receivable		10	10	—	—
Liabilities
Promissory note		200	200	—	—
Debentures		2,244	2,223	—	—

N OTE 3 – L IQUIDITY

During the three months ended March 31, 2009, net cash and cash equivalents increased by $508,000. Net cash used in operations totaled $1.2 million, attributable primarily to the payment of claims on our expired Indiana and Maryland contracts which experienced high utilization of services during the contract terms. Cash used in investing activities is comprised of $978,000 for the acquisition of CompCare by Core (purchase price of $1,500,000 less cash on hand at CompCare at time of acquisition of $522,000) and $6,000 in additions to property and equipment. This was offset by $4,000 in proceeds from payments received on notes receivable. Cash provided by financing activities consists primarily of $2.7 million in net proceeds from the issuance of common stock, offset by the repayment of debt of $14,000. At March 31, 2009, cash and cash equivalents amounted to $1.0 million.

N OTE 4 – S OURCES O F R EVENUE

Our revenue can be segregated into the following significant categories (amounts in thousands):


	Three Months Ended March 31,
	2009		2008
At-risk contracts	$	2,677	9,087
Administrative services only contracts		547	236
Pharmacy contracts		177	10
Other		4	—

Sub total	$	3,405	9,333
Less: Pre-acquisition revenues		710	—

Total	$	2,695	9,333

-13-

At-risk revenues include contracts under which we assume the financial risk for the costs of member behavioral healthcare services in exchange for a fixed, per member per month fee. For administrative services only contracts, we may manage behavioral healthcare programs or perform various managed care functions, such as clinical care management, provider network development, and claims processing without assuming financial risk for member behavioral healthcare costs. Under Pharmacy contracts, we manage behavioral pharmaceutical services for the members of health plans on an at-risk or ASO basis. Other revenues represent commissions earned through the sale of durable goods.

N OTE 5 – M AJOR C USTOMERS /C ONTRACTS

(1) We currently furnish behavioral healthcare services to approximately 207,000 members of a health plan providing Medicaid and Medicare benefits. Services are provided on an at-risk and administrative services only (“ASO”) basis. The contract accounted for 22.8% of our revenues for the three-month period ended March 31, 2009 and 8.6% of our revenues for the three months ended March 31, 2008. The health plan has been a customer since June of 2002. The initial contract was for a one-year period and has been automatically renewed on an annual basis. Termination by either party may occur with 90 days written notice to the other party.

(2) We currently contract with a HMO to provide behavioral healthcare services to approximately 182,000 Medicaid and Medicare members on an at-risk and ASO basis. Our contract with the HMO accounted for 26.8% of our operating revenues for the quarter ended March 31, 2009 and 8.5% of our operating revenues for the quarter ended March 31, 2008. The initial contract was for a one-year term and has been automatically renewed on an annual basis. Termination by either party may occur with 90 days written notice to the other party. The HMO has been a customer since June 2003.

In general, our contracts with our customers are typically for initial one-year terms, with automatic annual extensions. Such contracts generally provide for cancellation by either party with 60 to 90 days written notice.

N OTE 6 – C OMMON S TOCK

During the quarter ended March 31, 2009, the following changes in our Common Stock balances occurred:

•

Core, the owner of 14,400 shares of our Series A Convertible Preferred Stock that it had purchased from Hythiam, Inc., converted such preferred stock into 4,553,136 shares of common stock.

•

As part of the merger with Core on January 20, 2009, we issued 10,294,725 shares of our common stock to the holders of Core’s Class A common shares in a one-for-one exchange. Part of the Core Class A shares exchanged included 4,474,725 shares issued during January 2009 for net proceeds of approximately $1.1 million.

•

During February 2009, we completed three private placements of our common stock aggregating to 6,542,857 shares and generating a total of $1,650,000 in cash proceeds.

•

On February 27, 2009, Core cancelled the common stock certificate representing the 4,553,136 shares acquired from the earlier Series A Convertible Preferred Stock conversion. Core also cancelled an additional 1,739,130 common shares it had purchased from Hythiam at the time of acquiring the Series A Preferred Stock.

•

In March 2009, we issued 500,000 common shares to an employee pursuant to the requirements of an employment contract.

N OTE 7 – P REFERRED S TOCK

During the quarter ended March 31, 2009, the following changes in our Preferred Stock issuances and balances occurred:

•

For the purpose of completing the merger with Core, we designated two new series of Preferred Stock, Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock. The Series B-1

-14-

Preferred Stock and the Series B-2 Preferred Stock will automatically become convertible into their respective securities upon the satisfaction of the following conditions (the “Conversion Conditions”) (i) filing of an amendment to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of Common Stock to 100,000,000 shares and to increase the authorized number of shares of Preferred Stock to 1,000,000 shares and (ii) filing a Certificate of Designation designating a series of Series C Convertible Preferred stock, par value $50.00 per share (“Series C Preferred Stock”) of the Company having such rights, preferences and privileges as are set forth in an exhibit to such Certificate and (iii) authorizing the Company to issue a number of shares of such class equal to the number of shares of Series C Preferred Stock into which the Series B-1 Preferred Shares will be converted upon the satisfaction of the Conversion Conditions.

Subject to the Conversion Conditions, the Series B-1 Preferred Stock will be initially converted into an aggregate of 14,400 shares of Series C Preferred Stock. The initial per share conversion rate shall be one share of Series B-1 Preferred Stock for 8.597015 shares of Series C Preferred Stock. The Series C Preferred Stock will initially be convertible into Common Stock at the rate of approximately 316.28 shares of Common Stock for each share of Series C Preferred Stock, which conversion rate will be adjusted for certain dilutive issuances of Common Stock.

Subject to the Conversion Conditions, the Series B-2 Preferred Stock will be initially converted into an aggregate of 7,246,871 shares of Common Stock. The initial per share conversion rate shall be one share of Series B-2 Preferred Stock for 2,719.273546 shares of Common Stock, subject to any adjustments. The issuance of shares of Common Stock upon the conversion of the Series B-2 Preferred Stock will be made through a private placement exemption not involving a public offering under Section 3(a)(9) under the Securities Act and will be exempt from registration obligations under Section 5 of the Securities Act.

In addition to the conversion rights described above, the Series B-1 Preferred Stock have other rights and preferences, including the following:

•

to designate representatives to appoint a majority of our Board of Directors;

•

to prevent the creation and issuance of capital stock with rights equal or superior to those of the Series B-1 Preferred Stock;

•

prior consent for a sale or merger including a material portion of our assets or business; and

•

prior consent before entering into any single or series of related transactions exceeding $5,000,000 or incurring any debt in excess of $5,000,000.

Upon the filing of the Certificate of Designation, Preferences and Rights of Series C Convertible Preferred Stock of Comprehensive Care Corporation, a copy of which is set forth in Exhibit 99.2 to our Current Report on Form 8-K filed with the SEC on January 23, 2009, the rights and preferences of the Series C Preferred Stock will include, among other things, the following:

Liquidation Preferences. With respect to the distribution of assets upon liquidation, dissolution or winding-up, or the change of control of the Company, the Series C Preferred Stock will rank senior to all other designated series of the Company’s preferred stock. Upon any such liquidation, dissolution, winding-up or the change of control, each share of Series C Preferred Stock is entitled to receive an amount equal to $250.00 per share.

Dividends. Holders of Series C Preferred Stock (the “Series C Holders”) are entitled to receive a dividend when and if a dividend is declared by the Board of Directors of the Company with respect to the Common Stock in a per share amount equal to the dividend declared with respect to the Common Stock multiplied by the number of shares of Common Stock into which a share of Series C Preferred Stock is then converted.

Voting Rights. Except as required by law, the Series C Holders are entitled to notice of any stockholders’ meeting, to vote on any matters on which the Common Stock may be voted and to vote together with the Common Stock as a single class on all matters submitted to a vote of the Company’s stockholders. Each share of Series C Preferred Stock is entitled to the number of votes equal to the

-15-

number of shares of Common Stock into which the share of Series C Preferred Stock is then convertible. In addition to the general voting rights, the Series C Holders, voting as a separate class will initially be entitled to elect five directors of the company. If, at any time after the issuance of the original issuance of the shares of Series C Preferred Stock the number of shares of then-outstanding Series C Preferred Stock falls below 50% of the number of shares originally issued, then the Series C Holders will be entitled to elect the number of directors of the Company set forth in the table below.


Percentage of Originally Issued Shares of Series C Preferred Stock Outstanding		Number of Directors the Series C Preferred Stock is Entitled to Elect as a Separate Class
at least 40% but less than 50%		Four directors
at least 30% but less than 40%		Three directors
at least 20% but less than 30%		Two directors
at least 10% but less than 20%		One directors
Less than 10%		Zero directors

So long as at least a majority of the shares of Series C Preferred Stock originally issued by the Company are outstanding, the Company will not, without the affirmative vote of the holders of at least 50% of the outstanding Series C Preferred Stock, take certain actions, including the following:

•

create, authorize or issue any shares of any security or class of stock ranking senior to, or pari passu with, the Series C Preferred shares;

•

amend, alter or repeal the Certificate of Incorporation or Bylaws of the Corporation;

•

redeem or repurchase, or declare or pay any dividend or distribution with respect to, any equity securities;

•

effect (i) any sale, transfer, lease, merger or reorganization involving a material portion of the Corporation’s assets or business, (ii) transactions resulting in a change in control of the Company, or (iii) enter into any single or a series of related transactions with a valuation in excess of $5,000,000;

•

increase the size of the Board of Directors of the Corporation;

•

alter or change the rights of the Series C Preferred Stock or increase the authorized number of shares of Common Stock or Preferred; or

•

create or suffer to exist any new indebtedness in excess of $5,000,000.

•

In connection with the merger, all 14,400 shares of previously outstanding Series A Convertible Preferred Stock were converted into 4,553,136 shares of common stock.

•

The Series A Convertible Preferred Stock Certificate of Designation was withdrawn and all previously designated shares of Series A Preferred Stock were returned to their status as authorized Preferred Stock available for issuance.

•

A Certificate of Designation, Preferences and Rights of Series D Convertible Preferred Stock was filed with the Secretary of State of Delaware, the Company’s state of incorporation. The Certificate of Designation provides for the issuance of 7,000 shares of Series D stock, $50.00 par value, none of which had been issued as of March 31, 2009. Shares of Series D Preferred Stock may only be acquired by the exercise of warrants, 190 of which were issued March 31, 2009 to the members of our board of directors. Each warrant to purchase shares of Series D Preferred Stock may be exercised at any time between the warrants’ issuance and March 31, 2012 at an exercise price of $25,000 per share of Series D Preferred Stock. Each share of Series D Preferred Stock acquired through exercise of a warrant is convertible into 100,000 shares of common stock at any time.

-16-

If any dividend is declared with respect to the common stock of the Company, then holders of Series D Preferred Shares will be entitled to receive a dividend with respect to each Series D Preferred Share in an amount equal to (a) 50% of the amount of the dividend declared with respect to each share of common stock, multiplied by (b) the number of common stock shares into which such Series D Preferred Share is entitled to convert. Any dividends declared with respect to Series D Preferred Shares will be subordinate and junior to any dividends declared with respect to any other designated series of Preferred Stock then outstanding unless the certificate of designation of such series of Preferred Stock expressly states that any dividend thereon shall be subordinate and junior to any dividend declared with respect to the Series D Preferred Shares.

With respect to the distribution of assets upon liquidation, dissolution or winding-up, or the change of control of the Company, after payment of all amounts owing to holders of shares of any other capital stock of the Company ranking senior to the Series D Preferred Shares as to payment of dividends, the holders of Series D Preferred Shares will be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, before any payment shall be made to the holders of Common Stock or any other class or series of capital stock ranking junior to the Series D Preferred Shares by reason of their ownership thereof, an amount equal to $50.00 per Series D Preferred Share.

We are authorized to issue 18,740 shares of Preferred Stock, $50.00 par value, in one or more series, each series to have such designation and number of shares as the Board of Directors may fix prior to the issuance of any shares of such series. As of March 31, 2009, 4,340 shares were issued. Each series may have such preferences and relative participation, optional or special rights with such qualifications, limitations or restrictions stated in the resolution or resolutions providing for the issuance of such series as may be adopted from time to time by the Board of Directors prior to the issuance of any such series.

N OTE 8 – C OMMITMENTS AND C ONTINGENCIES

(1)

Related to our discontinued hospital operations, Medicare guidelines allow the Medicare fiscal intermediary to re-open previously filed cost reports. Our fiscal 1999 cost report, the final year we were required to file a cost report, is being reviewed, in which case the intermediary may determine that additional amounts are due to or from Medicare. Management believes cost reports for fiscal years prior to fiscal 1999 are closed and considered final.

(2)

In April 2009 a complaint entitled “MDwise, Inc. vs. Comprehensive Behavioral Care, Inc.” was filed against the Company in the Marion County Superior Court in Indiana by our former Indiana client seeking unspecified damages and a declaratory judgment requiring the Company to pay outstanding provider claims that are allegedly the Company’s responsibility under the expired contract. On May 8, 2009 the Company filed a motion to move the case to federal court. At the time of filing this report on Form 10-Q, the Company was preparing a counterclaim and intends to vigorously defend the claims alleged by MDwise. Until the actions are withdrawn or settled, the Company may incur further legal defense fees and may be subject to awards of plaintiff’s attorney fees or other fees, the amounts of which are not estimable. See Part I, Item 3, “Legal Proceedings” for a description of this matter.

N OTE 9 – R ELATED P ARTY T RANSACTIONS

In March 2009, we executed new employment agreements with our Chief Executive Officer, our new Chief Financial Officer, and our Chief Accounting Officer. The agreements are for terms of three years and contain provisions that include salary deferral, signing bonuses, and incentive compensation, among other items. Each contract also stipulates payments due each employee upon termination due to a change in control. At March 31, 2009, approximately $49,000 of compensation payments have been deferred to our Chief Executive Officer and $17,000 to our Chief Financial Officer. For further information concerning these agreements, see Exhibits 10.21, 10.22, and 10.23 to our Form 10-K dated December 31, 2008 and filed March 27, 2009 with the SEC at www.sec.gov.

-17-

N OTE 10 – S EGMENT I NFORMATION

Summary financial information for our two reportable segments and Corporate and other is as follows:


(Amounts in thousands)	Three Months Ended March 31,
	2009			2008
Managed Care
Revenues	$	3,401		$	9,333
Gross Margin		578			(406	)
Income/(loss) before income taxes		44			(1,177	)

Consumer Marketing
Revenues		4			—
Gross Margin		3			—
Income/(loss) before income taxes		(189	)		—

Corporate and Other
Revenues		—			—
Gross Margin		—			—
Income/(loss) before income taxes		(5,556	)		(252	)

Consolidated Operations
Revenues		3,405			9,333
Gross Margin		581			(406	)
Income/(loss) before income taxes		(5,701	)		(1,429	)

Pre-acquisition loss before income taxes		(720	)		—

Income/(loss) before income taxes – post-acquisition		(4,981	)		(1,429	)

N OTE 11 – S UBSEQUENT E VENTS

On May 11, 2009, Clark Marcus was appointed as the Company’s Co-Chief Executive Officer, a Director and as Chairman of the Board. Mr. Marcus will report to the Board of Directors. The material terms of his employment agreement include a term of three years and a base salary of $700,000 per annum increased by an amount no less than an amount equal to the percentage increase in the consumer price index for the metropolitan area of Mr. Marcus’ place of residence. In addition, Mr. Marcus will receive a sign on bonus of $80,000. This compensation may, at the election of the Company, be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay Mr. Marcus his stated compensation, after the payment by the Company of its operating expenses, but no longer than the end of each tax year. In addition, Mr. Marcus will be entitled to a special bonus in the amount equal to one percent of the Company’s pre-tax profits from the preceding year (as determined by the application of generally accepted accounting principles), up to the first $1,000,000 of such profits; plus an additional sum equal to two percent of the Company’s pre-tax profits for all sums over $1,000,000. In the event Mr. Marcus employment is terminated without cause twelve months from a change in control, the Company shall pay to Mr. Marcus a lump sum amount equal to the aggregate of (i) accrued unpaid salary, if any; (ii) accrued but unpaid expenses, if any; (iii) accrued but unpaid bonuses, if any; (iv) unissued warrants, if any; and (v) the total compensation which would have been paid to Mr. Marcus through five full years of compensation from the date of termination. On May 13, 2009, Mr. Marcus was granted 100 warrants to purchase Series D Convertible Preferred Stock.

On May 11, 2009, Dr. Jerry Katzman was appointed as the Company’s Executive Vice President of Strategic Development and as a Director. Dr. Katzman will report to the Board of Directors. The material terms of his employment agreement include a term of three years and a base salary of $390,000 per annum increased by an amount no less than an amount equal to the percentage increase in the consumer price index for the metropolitan area of Dr. Katzman’s place of residence. In addition, Dr. Katzman will receive a sign on bonus of $70,000. This

-18-

compensation may, at the election of the Company, be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay Dr. Katzman his stated compensation, after the payment by the Company of its operating expenses, but no longer than the end of each tax year. In addition, Dr. Katzman will be entitled to a special bonus in the amount equal to one percent of the Company’s pre-tax profits from the preceding year (as determined by the application of generally accepted accounting principles), up to the first $1,000,000 of such profits; plus an additional sum equal to two percent of the Company’s pre-tax profits for all sums over $1,000,000. In the event Dr. Katzman’s employment is terminated without cause twelve months from a change in control, the Company shall pay to Dr. Katzman a lump sum amount equal to the aggregate of (i) accrued unpaid salary, if any; (ii) accrued but unpaid expenses, if any; (iii) accrued but unpaid bonuses, if any; (iv) unissued warrants, if any; and (v) the total compensation which would have been paid to Dr. Katzman through five full years of compensation from the date of termination. On May 13, 2009, Dr. Katzman was granted 100 warrants to purchase Series D Convertible Preferred Stock.

I TEM 2.

M ANAGEMENT ’ S D ISCUSSION AND A NALYSIS OF F INANCIAL C ONDITION AND R ESULTS OF O PERATIONS

In addition to historical information, the following information contains forward-looking statements as defined under federal securities laws. Such statements include, but are not limited to, statements concerning the projected successful integration of the operations of Core Corporate Consulting Group, Inc. (“Core”) into CompCare’s business, the continuing success that Core is expected to have in marketing its products, the potential represented by ethnic markets and the overall performance of the healthcare market, our anticipated operating results, financial resources, increases in revenues, increased profitability, interest expense, growth and expansion, and the ability to obtain new behavioral healthcare contracts. These statements are based on current expectations, estimates and projections about the industry and markets in which we operate, and management’s beliefs and assumptions. Forward-looking statements are not guarantees of future performance and involve certain known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability of our at-risk contracts, cost of care, seasonality, our ability to obtain additional financing, and other risks detailed herein and from time to time in our SEC reports. The following discussion should be read in conjunction with the accompanying consolidated financial statements and notes thereto of CompCare appearing elsewhere herein.

OVERVIEW

GENERAL

Comprehensive Care Corporation (referred to herein as the “Company,” “CompCare,” “we,” “us” or “our”) is a Delaware corporation organized in 1969 that provides health care services and products through its primary operating subsidiaries, Comprehensive Behavioral Care, Inc. (“CBC”) and Core Corporate Consulting Group, Inc. (“Core”).

CBC and its subsidiaries

Primarily through CBC and its subsidiaries, we provide managed care services in the behavioral health and psychiatric fields. Recent federal and state legislation provides a new focus for CBC in specialty behavioral health care areas such as Autism Spectrum Disorders (“ASD”) and Attention Deficit Disorder (“ADD”). Additionally, CBC provides analytic services for its health plan customers to integrate medical claims data and pharmacy data into actionable information so patient care can be coordinated cost effectively. We coordinate and manage the delivery of a continuum of psychiatric and substance abuse services and products to:

•

Commercial members

•

Medicare members

•

Medicaid members

•

Children’s Health Insurance Program (“CHIP”) members

on behalf of:

-19-

•

health plans

•

government organizations

•

third-party claims administrators

•

commercial purchasers

•

other group purchasers of behavioral healthcare services

Our customer base includes both private and governmental entities. We provide services primarily by a contracted network of providers that includes:

•

psychiatrists

•

psychologists

•

therapists

•

other licensed healthcare professionals

•

psychiatric hospitals

•

general medical facilities with psychiatric beds

•

residential treatment centers

•

other treatment facilities

The services provided through our provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), and inpatient and crises intervention services. We do not directly provide treatment or own any provider of treatment services.

We typically enter into contracts on an annual basis to provide managed behavioral healthcare and substance abuse treatment to our clients’ members. Our arrangements with our clients fall into two broad categories:

• at-risk, capitation arrangements where our clients pay us a fixed fee per member in exchange for our assumption of the financial risk of providing services, and

• fee-for-service and capitated administrative services only (“ASO”) arrangements where we may manage behavioral healthcare programs or perform various managed care services.

Under capitation arrangements, the number of covered members as reported to us by our clients determines the amount of premiums we receive, which is independent of the cost of services rendered to members. The amount of premiums we receive for each member is fixed at the beginning of the contract term. These premiums may be subsequently adjusted, up or down, generally at the commencement of each renewal period.

Over the last several years we have experienced a trend with our clients to contract for services more on a at-risk basis than on an ASO basis. However, during 2008 the Company placed more focus on Administrative Services Only (“ASO”) contracts to obtain a better balance of risk and non-risk clients.

Our largest expense is the cost of behavioral health services that we provide, which is based primarily on our arrangements with healthcare providers. Since we are subject to increases in healthcare operating expenses based on an increase in the number and frequency of our members seeking behavioral care services, our profitability depends on our ability to predict and effectively manage healthcare operating expenses in relation to the fixed premiums we receive under capitation arrangements. Providing services on a capitation basis exposes us to the risk that our contracts may ultimately be unprofitable if we are unable to anticipate or control healthcare costs. Estimation of healthcare operating expense is our most significant critical accounting estimate. See “Management’s Discussion and Analyses of Financial Condition and Results of Operations — Critical Accounting Estimates.”

CBC Has Completed its Restructuring

In January 2008, CompCare appointed John Hill as its new Chief Executive Officer and President and charged him with the responsibility of restructuring CBC’s poor financial performance. Following a review of operations and all sales contracts, Mr. Hill formed a strategic plan and immediately began implementation.

The plan identified changes to CBC’s operations to better streamline it processes. CBC began to re-organize its operations in Q2 of 2008 and completed this restructuring in Q4 of 2008. As a result of the restructuring of CBC and the expiration of unprofitable contracts that were not renewed, CBC was able to reduce its costs. As a result, CBC posted a gross margin for the quarter ended March 31, 2009 compared to a loss in the corresponding quarter of 2008.

Core and its Subsidiary

Core provides consumer marketing services nationwide. Core was incorporated in Delaware on September 8, 2008. Core’s management and investors recognized a need in the insurance market for products for segments of the population with underserved healthcare needs. While some sectors of the United State’s population are aware of and receive Medicaid and/or Medicare, that coverage in and of itself is insufficient to service the needs of the populations identified above and may not be accessed by many individuals in those sectors by reason of lack of knowledge.

In addition, Core’s management also believes that there is a lack of medical records for the underserved segments of the country’s population, with most patients’ medical records being kept only at their physician’s or hospital’s offices. Simply put, in the event of emergency and/or sudden displacement of individuals (such as occurs during catastrophic events such as hurricanes), the medical records of these individuals are very difficult to access, which could lead to misdiagnosis, mistreatment or other negative consequences.

Core was formed with the purpose of establishing distribution channels sufficient to reach the majority of those underserved populations described above, which channels can be established both privately and through government facilities. In addition, distribution methods can be economically provided so that the general financial impact on our society is minimized with the net result being that a substantially greater number of the members of our society can receive medical treatment at a price affordable to all.

In November 2008, Core acquired Direct Ventures International, Inc. (“DVI”). DVI brings expertise in the sourcing of various items, including durable medical equipment and the distribution of this type of equipment. As a result of DVI, Core has contracted with various inbound and outbound telemarketing facilities having licensed, insurance telemarketers operating throughout the U.S. and abroad to market Core’s products. An inbound telemarketing company receives calls from potential customers to purchase products in response to a marketing program communicated through advertising efforts on the Internet, in print media, in television programming, or radio broadcasts, etc. An outbound telemarketing facility will initiate calls to potential customers to introduce a company, product or service, but must comply with Do Not Call legislation required by each State.

Core’s products include:

Core markets it products under the CoreSelect ^™ brand name.

Core Select ^™ products include:

Ø LifeGuide247 ^™ -

This is a 24-hour service that provides guidance through life’s difficult situations, such as job stress, financial troubles, relationships, grievance and simply legal matters. Service is available online or by telephone.

Ø Emergency Vital Records -

This product provides access to members’ vital medical records to emergency responders in the case of an emergency. Paramedics and emergency room practitioners can now access a member’s medical record quickly and easily in cases where the member may not be able to provide key information at such a critical time. The product provides the 25 key questions patients need to provide an emergency room. We have immediate interest in this product.

Ø Home Warranty Program -

This is a home warranty program and is available in three different coverage levels. It provides repair and protection for home appliances, electrical, plumbing, lock repair, etc.

Ø Hyperlink Agency-

This is a product that will allow an individual to become a licensed insurance agent. Our product is an “agent in a box” concept that guides you through the entire process of getting licensed to sell insurance products. After the person is successfully licensed we will provide them insurance and other products that they can sell. This via a joint venture with Hyperlink. The agents will simply identify the leads and direct them to a toll free number where the product can be purchased by phone. All of the sales will be completed by Hyperlink in their licensed call center environment. Additional products will be made available to these agents that do not require a license. These will initially include; LifeGuide247, Home Warranty’s, Identity theft packages, EVR and Pharmacy programs. Plus if the affiliate is not licensed to sell insurance, they can still sell insurance products and earn money as well.

Ø Vision/Dental -

These are inexpensive discount programs. They are low cost but an excellent annuity.

Ø Other Insurance Products –

Via our relationship with Hyperlink we have access to a full suite of insurance products. These can be offered as enhancements to existing product promotions or sold as the primary offering.

Ø Pharmacy Discounts-

This is a prescription discount program. The program incorporates 2 tiers. Tier one is a free card that gives discounts on prescriptions. The second provides deeper discounted rates on name brand and generic prescriptions. Version 2 has incorporates a monthly fee.

-20-

RECENT DEVELOPMENTS

We expect to mail in May 2009 an Information Statement to stockholders of record January 9, 2009 notifying shareholders of an action taken by written consent by the holders of 58.2% of our outstanding voting capital stock to amend the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of our common stock from 30,000,000 shares to 100,000,000 shares and to increase the number of authorized shares of our preferred stock from 60,000 shares to 1,000,000 shares.

In February 2009, CompCare obtained additional equity financing in the amount of $1.6 million through the sale of 6.4 million shares of its unregistered common stock to two investors. We intend to use the net proceeds from the sale of the securities for working capital purposes and to accelerate sales and marketing efforts to acquire new business. For further information, see our Form 8-K dated February 25, 2009 and filed March 3, 2009, available at www.sec.gov.

MERGER WITH CORE

On February 26, 2009, Giuseppe (Joe) Crisafi was appointed as the Company’s Chief Financial Officer and as a Board of Directors member. On February 25, 2009, Robert J. Landis resigned from the Board and was appointed as the Company’s Chief Accounting Officer.

Pursuant to a resolution approved at a meeting of our Board of Directors held on February 26, 2009, we authorized our transfer agent to cancel 6,292,266 common shares held by our wholly owned subsidiary, Core.

On January 21, 2009, we appointed the following persons as directors of the Company: Arnold B. Finestone, Sharon Kay Ray, Joshua I. Smith, and Arthur K. Yeap. On the same day, Mr. Finestone was appointed Chairman of the Board, Mr. Smith was named Vice Chairman of the Board, and the Audit and Compensation & Stock Option Committees were reconstituted. The Audit Committee is now comprised of Mr. Finestone (Chairman), Mr. Smith and Mr. Yeap, and the Compensation and Stock Option Committee is comprised of Ms. Ray, Mr. Finestone, and Mr. Yeap (Chairman).

On January 20, 2009, we entered into an Agreement and Plan of Merger (the “Merger”) with Core, a privately held Delaware corporation. The Merger was accomplished by merging our wholly owned subsidiary, CompCare Acquisition, Inc., with and into Core, with Core continuing as the surviving corporation and becoming a wholly-owned direct subsidiary of CompCare. All 10,294,725 outstanding shares of Core’s Class A Common Stock were exchanged for 10,294,725 shares of CompCare common stock. Each outstanding share of Core’s Class B Common Stock was exchanged for newly designated CompCare Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock, which in aggregate are convertible into the equivalent of 11,801,250 common shares. As a result of the Merger, the former Core stockholders became the holders of 77% of the voting power of the Company.

On January 20, 2009, Woodcliff Healthcare Investment Partners LLC (“Woodcliff”), a wholly-owned subsidiary of Hythiam, Inc. and our then largest stockholder, entered into a Stock Purchase Agreement with Core and Hythiam, pursuant to which Core purchased all 14,400 shares of Series A Convertible Preferred Stock and all 1,739,130 shares of common stock of the Company owned by Woodcliff. The Series A Preferred Stock purchased by Core represented 100% of our outstanding shares of Series A Preferred Stock. Prior to the Merger, Core converted all of its Series A Preferred Stock into 4,553,136 shares of common stock of the Company.

In connection with the closing of the Merger and not as the result of any disagreement with the Company, Michael Bakst, Ph.D. and Vijay Chevli resigned as directors of the Company on January 20, 2009. Mr. Chevli was the Chair of the Audit Committee and Special Committee of the Board.

In connection with Core’s anticipated purchase of the CompCare securities from Woodcliff and not as the result of any disagreement with the Company, Steven R. Peskin, M.D., Michel A. Sucher, M.D., and Michael Yuhas resigned as directors of the Company, effective January 16, 2009. Dr. Sucher was the Chair of the Compensation and Stock Option Committee and Dr. Peskin was the Chair of the Nominating and Corporate Governance Committee.

-21-

In January 2009, prior to the merger, Core raised additional capital of approximately $1.1 million through the sale of 4,474,725 of its Class A common shares to one investor. Such shares were exchanged for 4,474,725 shares of CompCare common stock as part of the merger on January 20, 2009. These proceeds, along with existing cash, were used to purchase the CompCare shares owned by Hythiam.

R ESULTS OF O PERATIONS

For the three months ended March 31, 2009, we reported an operating loss of $5.7 million and a net loss of $5.0 million, or $0.22 loss per share (basic and diluted).

The following table summarizes the Company’s operating results from continuing operations combining Core and CompCare for the three months ended March 31, 2009 and for CompCare only for the three months ended March 31, 2008 , being the predecessor corporation (amounts in thousands):


	C OMP C ARE AND C ORE FOR THE PERIOD J ANUARY 1, 2009 TO M ARCH 31, 2009			( PREDECESSOR ) C OMP C ARE FOR THE PERIOD J ANUARY 1, 2008 TO M ARCH 31, 2008
Operating revenues:
At-risk	$	2,677		$	9,087
Administrative services only (ASO)		547			236
Pharmacy		177			10
Other revenues		4			—

Total revenues		3,405			9,333

Costs of services and sales:
Claims expense		1,589			8,150
Other healthcare operating expenses		1,030			1,589
Pharmacy expenses		204			—
Other costs of services and sales		1			—

Total costs of services and sales		2,824			9,739

Gross margin		581			(406	)
Other Expenses:
General and administrative expenses		1,136			913
Recovery of doubtful accounts		(2	)		—
Depreciation and amortization		148			40

Total operating expenses		1,282			953
Merger transaction costs		589			—
Equity based expenses		4,361			35

Total expenses		6,232			988

Operating loss before pre-acquisition loss	$	(5,651	)	$	(1,394	)

Operating revenues from at-risk contracts decreased 70.5%, or $6.4 million, to $2.7 million for the three months ended March 31, 2009 compared to $9.1 million for the three months ended March 31, 2008. The decrease is primarily attributable to the expiration of two major customer contracts accounting for $6.1 million of business. Revenue associated with ASO contracts increased 131.8%, or approximately $311,000, to $547,000 for the three months ended March 31, 2009, compared to $236,000 for the three months ended March 31, 2008, due primarily to the addition of a new ASO contract. Pharmacy revenue increased from $10,000 for the three months ended March 31, 2008 to $177,000 for the three months ended March 31, 2009 due to CBC’s new Puerto Rico contract that combines behavioral pharmaceutical management services with traditional behavioral managed care.

Claims expense on at-risk contracts decreased approximately $6.6 million or 80.5% for the three months ended March 31, 2009, as compared to the three months ended March 31, 2008, due to the aforementioned expiration of two customer contracts. The decrease in claims expense as a percentage of at-risk revenues from

-22-

89.7% for the three months ended March 31, 2008 to 59.4% for the three months ended March 31, 2009 is attributable to the high medical loss ratios experienced from serving the members of these expired contracts. Other healthcare operating expenses, attributable to servicing both at-risk contracts and ASO contracts, decreased 35.2%, or approximately $559,000 due primarily to the reduction in the number of employees during the current quarter and the use of outside medical directors for patient reviews and case management. Pharmacy expense of $204,000 represents the cost of behavioral prescription drugs attributable to CBC’s new Puerto Rico contract. Overall, gross margin increased by $987,000 from a negative $406,000 for the three months ended March 31, 2008 to $581,000 for the three months ended March 31, 2009 due to the expiration of contracts with high utilization of behavioral services.

General and administrative expenses increased by 24.4%, or approximately $223,000 for the three months ended March 31, 2009 compared to the three months ended March 31, 2008. The increase is due to expenditures for increased sales and marketing efforts for Core and CompCare.

During the quarter ended March 31, 2009, there were $589,000 of merger related costs, consisting mainly of financial advisory fees and legal fees. Equity based expenses of $4.4 million is comprised of $4.2 million of expense recognized upon the issuance of the warrants to purchase Series D Convertible Preferred stock, $125,000 of expense related to the issuance of common stock to an employee pursuant to an employment agreement, and $91,000 of expense due to the early vesting of stock options as a result of the change in control.

S EASONALITY OF B USINESS

Historically, we have experienced increased member utilization during the months of March, April and May, and consistently low utilization by members during the months of June, July, and August. Such variations in member utilization impact our costs of care during these months, generally having a negative impact on our gross margins and operating profits during the months of March through May and a positive impact on our gross margins and operating profits during the June through August.

C ONCENTRATION OF R ISK

For the three months ended March 31, 2009, approximately 50%% of our operating revenue was concentrated in contracts with two health plans to provide behavioral healthcare services under Medicare and Medicaid plans. In addition, 65.0% of our operating revenue was attributable to health plan clients servicing Medicaid members in the state of Michigan. The term of each contract is generally for one year and is automatically renewable for additional one-year periods unless terminated by either party by giving the requisite written notice. The loss of one or more of these clients, unless replaced by new business, would negatively affect our financial condition.

We regularly maintain cash balances at our bank that exceed amounts covered by FDIC insurance. Should our bank cease operations, it would cause a significant disruption to our cash flow. We have recently opened new bank accounts at other banking institutions and have begun to spread our cash reserves in order to minimize any potential impact of a bank failure.

L IQUIDITY AND C APITAL R ESOURCES

During the three months ended March 31, 2009, net cash and cash equivalents increased by $508,000. Net cash used in continuing operations totaled $1.2 million. Cash used in investing activities is comprised of $978,000 for the acquisition of CompCare by Core (purchase price of $1,500,000 less cash on hand at CompCare at time of acquisition of $522,000) and $6,000 in additions to property and equipment. This was offset by $4,000 in proceeds from payments received on notes receivable. Cash provided by financing activities consists primarily of $2.7 million in net proceeds from the issuance of common stock, offset by the repayment of debt of $14,000.

At March 31, 2009, cash and cash equivalents were approximately $1.0 million. Although we had a working capital deficit of $5.4 million at March 31, 2009, we expect positive net cash flow from our existing contracts, as well as the addition of new contracts and, as a result, management believes we will have sufficient cash reserves to sustain current operations over the next 12 months.

-23-

Our unpaid claims liability is estimated using an actuarial paid completion factor methodology and other statistical analyses. These estimates are subject to the effects of trends in utilization and other factors. Any significant increase in member utilization that falls outside of our estimations would increase healthcare operating expenses and may impact our ability to achieve and sustain profitability and positive cash flow. Although considerable variability is inherent in such estimates, we believe that our unpaid claims liability is adequate. However, actual results could differ from the $4.6 million claims payable amount reported as of March 31, 2009.

In January 2009, the Company underwent a merger with Core, which had previously purchased a 49% interest in the Company to increase the Company’s pipeline for selling opportunities and create additional distribution channels for product offerings from which additional positive cash flow is expected. In February and March 2009, the Company raised additional capital of $1.7 million for working capital purposes and the payment of accrued claims payable. Together with new managed behavioral health care business in Michigan and Puerto Rico, management believes the Company will generate sufficient working capital to sustain current operations during the next twelve months. Although management believes that the Company’s current cash position and anticipated revenue in 2009 will be sufficient to meet its current levels of operations, additional cash resources may be required should the Company wish to accelerate sales or complete one or more acquisitions. Additional cash resources may be needed if the Company does not meet its sales targets, exceeds its projected operating costs or if unanticipated expenses arise or are incurred. The Company does not currently maintain a line of credit or term loan with any commercial bank or other financial institution and has not made any other arrangements to obtain additional financing. We can provide no assurance that we will not require additional financing. Likewise, we can provide no assurance that if we need additional financing that it will be available in an amount or on terms acceptable to us, if at all. If we are unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms favorable to us, we may be unable to execute upon our business plan or pay our costs and expenses as they are incurred, which could have a material, adverse effect on our business, financial condition and results of operations.

C RITICAL A CCOUNTING E STIMATES

Our discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make significant estimates and judgments to develop the amounts reflected and disclosed in the consolidated financial statements, most notably our estimate for claims incurred but not yet reported (“IBNR”). On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates as a result of actual claims differing from our assumptions or conditions.

We believe our accounting policies specific to revenue recognition, accrued claims payable, premium deficiencies, goodwill, and equity based expense involve our most significant judgments and estimates that are material to our consolidated financial statements (see Note 1 – “Description of the Company’s Business and Basis of Presentation” to the unaudited, consolidated financial statements).

R EVENUE R ECOGNITION

We provide managed behavioral healthcare and substance abuse services to recipients, primarily through subcontracts with HMOs. Revenue under the vast majority of these agreements is earned and recognized monthly based on the number of covered members as reported to us by our clients regardless of whether services actually provided are lesser or greater than anticipated when we entered into such contracts (generally referred to as capitation arrangements). The information regarding the number of covered members is supplied by our clients and we review membership eligibility records and other reported information to verify its accuracy in calculating the amount of revenue to be recognized. Consequently, the vast majority of our revenue is determined by the monthly receipt of covered member information and the associated payment from the client, thereby removing uncertainty and precluding us from needing to make assumptions to estimate monthly revenue amounts.

We may experience adjustments to our revenues to reflect changes in the number and eligibility status of members subsequent to when revenue is recognized. Subsequent adjustments to our revenue have not been material to date.

-24-

A CCRUED C LAIMS P AYABLE AND C LAIMS E XPENSE

Claims expense includes amounts paid to hospitals, physician groups and other managed care organizations under at-risk contracts. Healthcare expenses include items such as information systems, case management and quality assurance, attributable to both at-risk and ASO contracts.

The cost of behavioral health services is recognized in the period in which an eligible member actually receives services and includes an estimate of IBNR. We contract with various healthcare providers including hospitals, physician groups and other managed care organizations either on a discounted fee-for-service or a per-case basis. We determine that a member has received services when we receive a claim within the contracted timeframe with all required billing elements correctly completed by the service provider. We then determine whether (1) the member is eligible to receive such services, (2) the service provided is medically necessary and is covered by the benefit plan’s certificate of coverage, and (3) the service has been authorized by one of our employees. If all of these requirements are met, the claim is entered into our claims system for payment and the associated cost of behavioral health services is recognized. If the claim is denied, the service provider is notified and has appeal rights under their contract with us.

Accrued claims payable consists primarily of reserves established for reported claims and IBNR claims, which are unpaid through the respective balance sheet dates. Our policy is to record management’s best estimate of IBNR. The IBNR liability is estimated monthly using an actuarial paid completion factor methodology and is continually reviewed and adjusted, if necessary, to reflect any change in the estimated liability as more information becomes available. In deriving an initial range of estimates, we use an industry accepted actuarial model that incorporates past claims payment experience, enrollment data and key assumptions such as trends in healthcare costs and seasonality. Authorization data, utilization statistics, calculated completion percentages and qualitative factors are then combined with the initial range to form the basis of management’s best estimate of the accrued claims payable balance.

At March 31, 2009, the range of accrued claims payable was between $4.5 million and $4.7 million. Based on the information available, we determined our best estimate of the accrued claims liability to be $4.6 million. We have used the same methodology and assumptions for estimating the IBNR portion of the accrued claims liability for each quarter-end.

Accrued claims payable at March 31, 2009 is comprised of approximately $1.7 million of submitted and approved claims, which had not yet been paid, and $2.9 million for IBNR claims.

Many aspects of our managed care business are not predictable with consistency, and therefore, estimating IBNR claims involves a significant amount of management judgment. Actual claims incurred could differ from the estimated claims payable amount presented. The following are factors that would have an impact on our future operations and financial condition:

•

Changes in utilization patterns

•

Changes in healthcare costs

•

Changes in claims submission timeframes by providers

•

Success in renegotiating contracts with healthcare providers

•

Occurrence of catastrophes

•

Changes in benefit plan design

•

The impact of present or future state and federal regulations

A 5% increase in assumed healthcare cost trends from those used in our calculations of IBNR at March 31, 2009, could increase our claims expense by approximately $36,000 and reduce our net results per share by $0.002 per share as illustrated in the table below:

Change in Healthcare Costs:


(Decrease) Increase	(Decrease) Increase In Claims Expense
(5%)	$	(35,000	)
5%	$	36,000

-25-

P REMIUM D EFICIENCIES

At any time prior to the end of a contract or contract renewal, if a contract is not meeting its financial goals, we generally have the ability to cancel the contract with 60 to 90 days written notice. Prior to cancellation, we will submit a request for a rate increase accompanied by supporting utilization data. Although our clients have historically been generally receptive to such requests, no assurance can be given that such requests will be fulfilled in the future in our favor. If a rate increase is not granted, we have the ability, in most cases, to terminate the contract and limit our risk to a short-term period.

On a quarterly basis, we perform a review of our portfolio of contracts for the purpose of identifying loss contracts (as defined in the American Institute of Certified Public Accountants Audit and Accounting Guide – Health Care Organizations) and developing a contract loss reserve, if applicable, for succeeding periods. During the three months ended March 31, 2009, we did not identify any contracts where it was probable that a loss had been incurred and for which a loss could reasonably be estimated.

G OODWILL

We evaluate at least annually the amount of our recorded goodwill by performing impairment tests that compare the carrying amount to an estimated fair value. Management considers both the income and market approaches in the fair value determination. In estimating the fair value under the income approach, management makes its best assumptions regarding future cash flows and applies a discount rate to the cash flows to yield a present, fair value of equity. The market approach is based primarily on reference to transactions including the Company’s common stock and the quoted market prices of the Company’s common stock. As a result of such tests, management believes there is no material risk of loss from impairment of goodwill. However, actual results may differ significantly from management’s assumptions, resulting in a potentially adverse impact to our consolidated financial statements.

U NALLOCATED A SSETS

Unallocated assets on our balance sheet as of March 31, 2009 represents the excess of the implied purchase price of CompCare over the net tangible assets acquired, less estimated amortization recorded during the quarter ended March 31, 2009. We are in the process of obtaining fair market values for CompCare’s identifiable intangible assets, such as its customer contracts, NCQA accreditation and provider network. Upon completion of our valuation analysis, we will record the identifiable intangible assets at the appropriate amounts and assign the remaining excess, if any, to goodwill. An estimate for amortization has been made based on estimated values for intangible assets.

-26-

E QUITY B ASED E XPENSE

We have adopted SFAS 123R and elected to apply the modified-prospective method to measure expenses for stock options and warrants at fair value on the grant date and recognize these expenses on a straight-line basis over the service period for those options and warrants expected to vest. We use the Black-Scholes option pricing model, which requires certain variables for input to calculate the fair value of a stock award on the grant date. These variables include the expected volatility of our stock price, award exercise behaviors, the risk free interest rate and expected dividends. We use significant judgment in estimating expected volatility of the stock, exercise behavior and forfeiture rates.

Expected Volatility

We estimate the volatility of the share price by using historical data of our traded stock in combination with management’s expectation of the extent of fluctuation in future stock prices. We believe our historical volatility is more representative of future stock price volatility and as such it has been given greater weight in estimating future volatility.

Expected Term

A variety of factors are considered in determining the expected term of options granted. Options granted are grouped by their homogeneity, based on the optionees’ position, whether managerial or clerical, and length of service and turnover rate. Where possible, we analyze exercise and post-vesting termination behavior. For any group without sufficient information, we estimate the expected term of the options granted by averaging the vesting term and the contractual term of the options.

Expected Forfeiture Rate

We generally separate our option awards into two groups: employee and non-employee awards. The historical data of each group are analyzed independently to estimate the forfeiture rate of options at the time of grant. These estimates are revised in subsequent periods if actual forfeitures differ from estimated forfeitures.

L EGAL P ROCEEDINGS

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. Aside from the litigation described in Part II, Item 1, “Legal Proceedings,” as of the date of this report, we are not currently involved in any legal proceeding that we believe would have a material adverse effect on our business, financial condition or operating results.

I TEM 3.

Q UANTITATIVE AND Q UALITATIVE D ISCLOSURES A BOUT M ARKET R ISK

While we currently have market risk sensitive instruments, we have no significant exposure to changing interest rates, as the interest rate on our long-term debt is fixed. Additionally, we do not use derivative financial instruments for investment or trading purposes and our investments are generally limited to cash deposits.

I TEM 4.

C ONTROLS AND P ROCEDURES

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report, and, based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective. There have been no changes in our internal controls over financial reporting identified in connection with this evaluation that occurred during the period covered by this report that have affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

-27-

PART II – OTHER INFORMATION

I TEM 1.

L EGAL P ROCEEDINGS

In the ordinary conduct of our business, we are subject to periodic lawsuits and claims. Although we cannot predict with certainty the ultimate resolution of lawsuits and claims asserted against us, we do not believe that any currently pending legal proceedings to which we are a party will have a material adverse effect on our business, results of operations, cash flows or financial condition. Our policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. A determination of the amount of the liability required, if any, for these contingencies is made after an analysis of each known issue in accordance with SFAS No. 5, Accounting for Contingencies, and related pronouncements. In accordance with SFAS No. 5, a liability is recorded and charged to operating expense when we determine that a loss is probable and the amount can be reasonably estimated. Additionally, we disclose contingencies for which a material loss is reasonably possible, but not probable. Except as described below, as of March 31, 2009, there were no material contingencies requiring accrual or disclosure.

On April 16, 2009 we were served with a complaint entitled “MDwise, Inc. vs Comprehensive Behavioral Care, Inc.” filed in Marion County Superior Court in Indiana by our former major Indiana client seeking unspecified damages and a declaratory judgment requiring the Company to pay outstanding provider claims that are allegedly the Company’s responsibility under the expired contract with our former client. On May 8, 2009 the Company filed a motion to move the case to federal court. At the time of filing this report on Form 10-Q, the Company was preparing a counterclaim and intends to vigorously defend the claims alleged by MDwise.

In the opinion of management, the Company has reserves that are adequate to cover this litigation. Management believes that the resolution of this matter will not have a material adverse effect on the Company’s financial condition or results of operations; however there can be no assurance that we will not sustain material liability as a result of this claim.

I TEM 1A.

R ISK F ACTORS

The Risk Factors included in our Annual Report on Form 10-K for the year ended December 31, 2008 have not materially changed.

I TEM 2.

U NREGISTERED S ALES OF E QUITY S ECURITIES AND U SE OF P ROCEEDS

During the month of February 2009, we completed the following sales of our common stock, $0.01 par value, in private placements not involving a public offering:

•

On February 6, 2009, we sold 142,857 shares of our common stock, for gross proceeds of $50,000 to one accredited investor. The net proceeds to the Company from this sale were $45,000.

•

On February 24, 2009, we completed the sale of 6,000,000 shares of our common stock for gross proceeds of $1,500,000 and net proceeds of $1,400,000, for which a Current Report on Form 8-K was filed with the SEC on March 3, 2009.

•

On February 26, 2009, we completed the sale of 400,000 shares of our common stock for gross and net proceeds of $100,000, for which a Current Report on Form 8-K was filed with the SEC on March 3, 2009.

Based on certain representations and warranties of the purchasers in their respective Subscription Agreements, we relied on Section 4(2) of the Securities Act for an exemption from the registration requirements of the Securities Act. The shares purchased have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from registration requirements. We intend to use the net proceeds for product and sales expansion and working capital purposes.

-28-

I TEM 4.

S UBMISSION OF M ATTERS TO A V OTE OF S ECURITY H OLDERS

On January 14, 2009, the holders of 58.2% of our outstanding voting capital stock, voting together as a single class on an as-converted basis and the holders of all outstanding shares of CompCare’s Series A Convertible Preferred Stock, par value $50.00 per share, voting as a separate class, took action by written consent, dated January 14, 2009, in lieu of a special meeting of the stockholders, to ratify and approve amendments to our Restated Certificate of Incorporation to:

•

increase the number of authorized shares of the Company’s common stock, $0.01 par value per share, from 30,000,000 shares to 100,000,000 shares, and to

•

increase the number of authorized shares of the Company’s preferred stock, $50.00 par value per share, from 60,000 shares to 1,000,000 shares.

All stockholders will be notified of the proposed amendment by an information statement on Schedule 14C expected to be mailed in May.

I TEM 5.

O THER I NFORMATION

C URRENT R EPORT ON F ORM 8-K, I TEM 3.02—U NREGISTERED S ALES OF E QUITY S ECURITIES

On May 13, 2009, the Company issued a stock purchase warrant to purchase up to 100 shares of the Company’s Series D Preferred Stock, par value $50.00 per share, to each of Mr. Clark Marcus and Dr. Jerry Katzman as an equity incentive to align the interests of the each newly appointed officer of the Company with those of the Company’s stockholders.

Each warrant to purchase shares of Series D Preferred Stock may be exercised at any time between its issuance and May 13, 2012, but not before the Company has effected an increase in its authorized capital, at an exercise price of $25,000 per share of Series D Preferred Stock, provided that neither warrant will be exercisable until the Restated Certificate has been filed with the Secretary of State of the State of Delaware. If after September 30, 2009, the Market Value of a share of Series D Preferred Stock exceeds the exercise price for a share of Series D Preferred Stock, then the holder may exercise the warrant by a cashless exercise and receive the number of shares of Series D Preferred Stock representing the net value of the warrant. The Market Value of a share of Series D Preferred Stock is equal to the product of (a) the per share market price of the Company’s common stock multiplied by (b) the number of shares of the Company’s common stock into which a share of Series D Preferred Stock is then convertible.

The number of shares of Series D Preferred Stock for which a warrant is exercisable is subject to adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting the Series D Preferred Stock. In the event of a Change of Control (as defined in the warrants) of the Company, the holder has the right to require the Company to redeem the warrant in exchange for an amount equal to the value of the warrant determined using the Black Scholes Option Pricing Model.

The foregoing description of the terms and conditions of the warrants is not purported to be complete and is qualified in its entirety by the form of warrant, which is filed as Exhibit 10.26 hereto and is incorporated by reference herein in its entirety.

In issuing the warrants, the Company is relying on an exemption from registration provided under Section 4(2) of the Securities Act of 1933, as amended (the “Act”), which exemption the Company believes is available because the securities were not offered pursuant to a general solicitation and the status of the purchasers of the shares as “accredited investors” as defined in Regulation D promulgated under the Act. This report is neither an offer to purchase, nor a solicitation of an offer to sell, securities. Neither the warrants nor the shares of Series of Series D Preferred Stock issuable upon their exercise have not been registered under the Securities Act and may not be offered in the United States absent registration or an applicable exemption from registration requirements.

-29-

C URRENT R EPORT OF F ORM 8-K, I TEM 5.02—D EPARTURE OF D IRECTORS OR C ERTAIN O FFICERS ; E LECTION OF D IRECTORS ; A PPOINTMENT OF C ERTAIN O FFICERS ; C OMPENSATORY A RRANGEMENTS OF C ERTAIN O FFICERS

On May 11, 2009, Clark Marcus, age 67, was appointed as the Company’s Co-Chief Executive Officer, a Director and as Chairman of the Board. Mr. Marcus will report to the Board of Directors. Mr. Marcus brings over 35 years of building public and private companies and strong relationships with business leaders and political associates. From 1993 to 2008, Mr. Marcus was one of the founders, CEO and Chairman of the Board of The Amacore Group, Inc., a premier healthcare distribution company whose sales grew from zero to over $30 million. In the late 1980’s, Mr. Marcus founded and initially funded Dimensional Vision Group Limited (DVG) and Fountain Pharmaceuticals, Inc., resulting in both companies engaging in a public offering within their first year. In the 1970’s and early 1980’s, Mr. Marcus was the driving force in the successful growth of a number of various private ventures. He was also a senior partner of the New York law firms of Victor & Marcus and Marcus & Marcus.

The material terms of his employment agreement include a term of three years and a base salary of $700,000 per annum increased by an amount no less than an amount equal to the percentage increase in the consumer price index for the metropolitan area of Mr. Marcus’ place of residence. In addition, Mr. Marcus will receive a sign on bonus of $80,000. This compensation may, at the election of the Company, be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay Mr. Marcus his stated compensation, after the payment by the Company of its operating expenses, but no longer than the end of each tax year. In addition, Mr. Marcus will be entitled to a special bonus in the amount equal to one percent of the Company’s pre-tax profits from the preceding year (as determined by the application of generally accepted accounting principles), up to the first $1,000,000 of such profits; plus an additional sum equal to two percent of the Company’s pre-tax profits for all sums over $1,000,000. In the event Mr. Marcus employment is terminated without cause twelve months from a change in control, the Company shall pay to Mr. Marcus a lump sum amount equal to the aggregate of (i) accrued unpaid salary, if any; (ii) accrued but unpaid expenses, if any; (iii) accrued but unpaid bonuses, if any; (iv) unissued warrants, if any; and (v) the total compensation which would have been paid to Mr. Marcus through five full years of compensation from the date of termination. A copy of Mr. Marcus’ employment agreement is filed as Exhibit 10.24 hereto and is incorporated by reference herein in its entirety.

On May 11, 2009, Dr. Jerry Katzman, age 56, was appointed as the Company’s Executive Vice President of Strategic Development and as a Director. Dr. Katzman will report to our Chairman and Co-Chief Executive Officer Clark Marcus. Dr. Katzman is a practicing ophthalmologist and from 1997 to August 2008 was the Chief Medical Officer of The Amacore Group, Inc., a premier healthcare distribution company. Dr. Katzman also served on the Board of Directors of Amacore until August 2008. Dr. Katzman is currently a member of the Physicians Advisory Council for the state of Florida. Dr. Katzman earned an MD degree from Unversidad de Guadalajara in Jalisco, Mexico and a BS in Biomedical Engineering from Boston University.

The material terms of his employment agreement include a term of three years and a base salary of $390,000 per annum increased by an amount no less than an amount equal to the percentage increase in the consumer price index for the metropolitan area of Dr. Katzman’s place of residence. In addition, Dr. Katzman will receive a sign on bonus of $70,000. This compensation may, at the election of the Company, be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay Dr. Katzman his stated compensation, after the payment by the Company of its operating expenses, but no longer than the end of each tax year. In addition, Dr. Katzman will be entitled to a special bonus in the amount equal to one percent of the Company’s pre-tax profits from the preceding year (as determined by the application of generally accepted accounting principles), up to the first $1,000,000 of such profits; plus an additional sum equal to two percent of the Company’s pre-tax profits for all sums over $1,000,000. In the event Dr. Katzman’s employment is terminated without cause twelve months from a change in control, the Company shall pay to Dr. Katzman a lump sum amount equal to the aggregate of (i) accrued unpaid salary, if any; (ii) accrued but unpaid expenses, if any; (iii) accrued but unpaid bonuses, if any; (iv) unissued warrants, if any; and (v) the total compensation which would have been paid to Dr. Katzman through five full years of compensation from the date of termination. A copy of Dr. Katzman’s employment agreement is filed as Exhibit 10.25 hereto and is incorporated by reference herein in its entirety.

On May 13, 2009, the Company’s Board of Directors approved the issuance of the warrants to purchase shares of Series D Preferred Stock to the following executive officers of the Company as set forth below:


Clark Marcus, Co-Chief Executive Officer		100 shares of Series D Preferred Stock
Dr. Jerry Katzman, Executive Vice President of Strategic Development		100 shares of Series D Preferred Stock

-30-

The Information set forth under Item 3.02 of set forth above is hereby incorporated by reference into this Item 5.02.

C URRENT R EPORT OF F ORM 8-K, I TEM 5.03—A MENDMENTS TO A RTICLES OF I NCORPORATION OR B YLAWS ; C HANGE IN F ISCAL Y EAR

On May 11, 2009, our Board of Directors adopted an amendment to Section 3.02 of the Company’s Amended and Restated Bylaws to revise the number of directors of the Company from seven to nine. The amendment is effective May 11, 2009.

I TEM 6.

E XHIBITS


EXHIBIT NUMBER		DESCRIPTION
3.8		Bylaw Amendment, effective May 11, 2009

10.24		Employment Agreement dated May 11, 2009 between the Company and Clark A. Marcus

10.25		Employment Agreement dated May 11, 2009 between the Company and Dr. Jerry Katzman

10.26		Form of Warrant to Purchase Series D Preferred Stock

31.1		Certification of Co-Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Co-Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.3		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of Co-Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Co-Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.3		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

-31-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	COMPREHENSIVE CARE CORPORATION
May 15, 2009

	By	/s/ JOHN M. HILL
		John M. Hill
		President and Co-Chief Executive Officer
		(Principal Executive Officer)

	By	/s/ CLARK A. MARCUS
		Clark A. Marcus
		Co-Chief Executive Officer
		(Principal Executive Officer)

	By	/s/ GIUSEPPE CRISAFI
		Giuseppe Crisafi
		Chief Financial Officer
		(Principal Financial Officer)

-32-

Exhibit 3.8

AMENDMENT TO THE AMENDED AND RESTATED BYLAWS

COMPREHENSIVE CARE CORPORATION

Adopted May 11, 2009

Section 3.02 of the Corporation’s Bylaws is amended in its entirety to read as follows:

“ General Powers and Number . The business and affairs of the Corporation shall be managed by the Board subject to any limitations set forth under the laws of the State of Delaware, the Articles of Incorporation, and these Bylaws concerning corporate action that must be authorized or approved by the stockholders. The number of directors of the Corporation shall be nine. The authorized number of directors can be changed from time to time only by a duly authorized amendment of this Section 3.02. No reduction of the number of directors shall have the effect of removing any director before that director’s term of office expires.”

-33-

Exhibit 10.24

EMPLOYMENT AGREEMENT

AGREEMENT made as of the 11th day of May, 2009, by and between Clark A. Marcus, an individual residing in Tampa, FL (hereinafter referred to as “Executive”) and Comprehensive Care Corporation, a Delaware corporation with its principle office located at 3405 W. Dr. Martin Luther King Jr. Blvd, Suite 101, Tampa, FL 33607 (hereinafter called the “Company”).

W I T N E S S E T H

WHEREAS, the Company desires to retain the services of Executive to render his/her services to Company on the terms and conditions hereinafter set forth; and

WHEREAS, Executive is agreeable to rendering such services to the Company on the terms and conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto, intending to be legally bound, hereby agree as follows:

Employment Term, Duties and Acceptance

(a) Company hereby retains Executive as Company’s Chairman of the Board and Co-Chief Executive Officer for a period of three (3) years, commencing on the date hereof (the “Employment Period”), subject to earlier termination as hereinafter provided, to render his/her services to Company upon the terms and conditions herein contained, in such executive capacity. In such executive capacity, Executive shall report and be responsible to the Company’s Board of Directors. Notwithstanding the foregoing and notwithstanding the fact that Executive’s employment shall commence immediately, the three-year term of Executive’s employment shall be calculated from the time Executive is paid his/her full compensation on a regular basis as set forth in paragraph 2 below.

(b) Executive hereby accepts the foregoing employment and agrees to render his/her services to the Company on a full-time basis in such a manner as directed by the Company’s Board as to reflect Executive’s best efforts to the end that the Company’s operations are properly managed. In furtherance of Executive performing the duties assigned to him/her under this Agreement, the Company agrees to provide Executive with a support staff reasonably required by Executive so as to enable him/her to carry out such duties.

Compensation

(a) During the first year of the term of this Agreement, Executive shall receive compensation of $700,000.00 per year. This compensation may, at the election of the Company, be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay the Company’s executives their stated compensation after the payment by the Company of its operating expenses. Executive’s compensation shall be payable in accordance with the general payroll practices of the Company as are from time to time, in effect, less such deductions or amounts as shall be required to be withheld by applicable law or regulation. On each yearly anniversary date of the execution of this Agreement (hereinafter sometimes called the “Anniversary Date,” in each yearly instance) the Board of Directors shall review the services provided by Executive to determine the amount that Executive’s salary shall be increased for the forthcoming yearly period. Such increase shall be no less than an amount equal to the percentage increase in the Consumer Price Index or such other similar index reflective of the cost of living increase in the metropolitan area of Executive’s place of residence from the beginning of the yearly period to the end of the yearly period with respect to the Consumer Price Index applicable to the said metropolitan area, times Executive’s base compensation in effect during the said yearly period. The sum resulting by way of this increase to the Executive’s base compensation shall, for the then immediately succeeding period be considered the Executive’s base compensation. The Board of Directors shall also determine on an annual (fiscal or calendar year, as the case may be) basis, the amount, if any, of bonus or incentives to be paid to Executive. Provided, however, that Executive shall receive a special bonus (“special bonus”) in an amount equal to one (1) percent of the Company’s pre-tax profits from the preceding year (as determined by the application of generally

-34-

accepted accounting principles), up to the first one-million dollars of such profits; plus an additional sum equal to two, and (2) percent of the Company’s pre-tax profits for all sums over one-million dollars The special bonus shall be paid within thirty (30) days following determination thereof, which determination shall be made as soon as practicable.

(b) Executive shall be entitled to reasonable paid vacation time, sick leave and time to attend professional meetings comparable to that offered the executives in comparable positions.

(c) Executive shall be entitled (subject to the terms and conditions of particular plans and programs) to all fringe benefits afforded to other senior executives of the Company, including, but not by way of limitation, bonuses and the right to participate in any pension, stock option, retirement and, unless otherwise covered by a group policy (as opposed to an individual policy owned and paid for by Executive and/or his wife and/or a company of which either of them own 100% of stock), major medical, group health, disability, relocation reimbursement, and other employee benefit programs made generally available, from time to time, by the Company. The Company also agrees to pay the premiums for Executive’s current life insurance policy and travel and accident insurance (with a double indemnity provision).

(d) Company shall pay or reimburse Executive for reasonable expenses incurred in the performance of his services under this Agreement during the Employment Period, upon presentation of expense statements, vouchers or such other supporting documentation as may reasonably be required.

(e) Company shall pay Executive a sign on bonus of $80,000 which, at the Company’s discretion, may be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay the Executive.

Disability

(a) Upon the disability, as defined in subparagraph 3(b) hereof, of Executive during the Employment Period, Company may, in its sole discretion, terminate Executive’s employment; provided that if the Company elects to so terminate Executive’s employment, Executive shall be entitled to receive, accrued but unpaid salary, expense reimbursement and bonuses, the proceeds of any disability insurance policy plus an amount from the Company monthly which, when added to the amount received by the Executive from any disability policy in effect for the Executive at the time of his disability will equal the Executive’s salary for a twelve-month period following the date of termination, as if the termination had not occurred. Such termination shall have no effect on the Company’s obligation to pay the special bonus referred to hereinbefore. Provided, however, in the event Executive partially perform and discharge the duties previously performed by him/her for Company, nothing herein shall prevent the Executive from continuing his/her duties in a part-time capacity, at a level of Compensation to be determined at that time.

(b) For purposes of this Agreement the term “disability” shall mean Executive’s inability to continue to materially and substantially perform and discharge the duties previously required of him/her on behalf of the Company for an aggregate period exceeding three (3) consecutive months within any twelve (12) month consecutive period.

(c) In the event of a dispute between the parties as to what constitutes a disability, such dispute shall be finally determined by a person mutually agreed upon by Executive and Company. If a mutually acceptable person cannot be selected, such designations shall be made by Executive and Company each choosing a person, which person shall then mutually select a third person (collectively called the “panel”). The panel’s determination shall be made by majority vote and such determination shall be deemed binding and conclusive. The parties agree to fully cooperate with whatever procedures and examinations may be required in order to allow the panel to make its determination.

Termination of Employment

(a) (i) In the event Fifty (50) Percent or more of the equity securities or all or substantially all of the assets of the Company are acquired by any single person or identifiable group, as defined by the applicable rules and regulations under the Security and Exchange Act of 1934, as amended and in the further event that Executive’s

-35-

employment is terminated, by either the Company or the Executive, within twelve (12) months following such event, except if such termination is by reason of “cause” (as that term is defined at paragraph 4(c) hereafter, or (ii) in the event Executive terminates his employment by reason of the uncured breach of this Agreement by Company (“cause”), then, on the termination date, Company shall pay (or issue, as the case may be) to Executive a lump sum amount equal to the aggregate of (i) accrued but unpaid salary, if any; (ii) accrued but unpaid expenses, if any; (iii) accrued but unpaid bonuses, if any; (iv) unissued warrants, if any; and (v) the total compensation which would have been paid to Executive through five full years of compensation from the date of termination. Additionally, as of the termination date, Executive’s rights to exercise his warrants, (if any) and/or stock option to the full extent of the shares covered thereby (if said rights had not otherwise matured or vested), shall forthwith mature and vest and Executive shall have the right to exercise his rights under any such securities. If the Executive intends to terminate his employment with the company for “cause”, he “cause” shall be specified in a written notice sent by Executive to the Company, and the Company shall be afforded fifteen (15) days or longer, if reasonably required, to cure such breach, if such breach is capable of being cured.

(b) In the event Fifty (50) Percent or more of the equity securities or all or substantially all of the assets of the Company are acquired by any single person or identifiable group, as defined by the applicable rules and regulations under the Security and Exchange Act of 1934, as amended, all unvested securities and benefits attributable to the Executive will immediately vest. In addition, with respect to any securities of the Company or rights to securities in the Company vesting in Executive as a result of this Article 4, the Company shall advise Executive by written notice at least four weeks prior to the Company’s filing of one or more registration statements under the Securities Act of 1933, as amended (or any successor form covering securities) to be offered and sold to the public generally, and shall, upon request of Executive, include in any such registration statement such securities of Executive as he/she may request. The foregoing shall include common stock of the Company to which Executive may be entitled by way of his/her exercise of any stock options and/or the exercise of warrants.

(c) In the event of misconduct in office by Executive in the performance of his/her duties hereunder (which shall hereinafter be referred to as “Termination for Cause”), Company may terminate this Agreement by giving two (2) weeks prior written notice to Executive identifying the cause of termination and specifying the effective date of such termination. If Executive is subjected to Termination for Cause, then such “cause” shall be specified in such notice and Executive shall be afforded thirty (30) days or longer, if reasonably required, to cure such breach, if such breach is capable of being cured. If Executive is unable to cure or if terminated pursuant to the provisions of paragraph “4.(c)”, Company shall pay to Executive the aggregate of (i) accrued but unpaid expenses, if any; and (ii) the net salary compensation which would have been paid to Executive through the date of termination. Furthermore, in that event any warrants to be issued pursuant to this Agreement, and any options granted pursuant to plans then applicable to Executive which have not then vested shall be forfeited as of the termination date.

(d) The failure of Executive’s representations herein to be materially accurate shall give the Company the right to terminate Executive’s engagement.

(e) In the event Executive resigns or is terminated as an employee of Company, Executive hereby agrees that his position(s) as officer and director of the Company shall automatically end as of the date of his resignation or termination of employment.

EXECUTIVE REPRESENTATIONS

Executive represents and warrants to the Company that:

(a) He/She has full right, power and authority to enter into this Agreement and perform the services and directions given to him/her by the Company’s Board of Directors, consistent with the Executive’s position of Co-Chief Executive Officer, free of any further obligation to any prior employer.

(b) The Executive is not subject to the restrictions of any restrictive covenants entered into between or among the Executive and other prior employer(s).

-36-

CONFIDENTIALITY

(a) Executive agrees to execute Company’s standard form of Confidentiality Agreement as prepared by Counsel to Company and annexed hereto as Schedule A.

(b) Executive’s covenants contained herein shall survive the termination or expiration of this Agreement.

TERMINATION OF AGREEMENT

This Agreement shall, in addition to other provisions affecting termination, terminate on the occurrence of any of the following events:

(a) Cessation of the Company’s business;

(b) Dissolution of the Company; or

NOTICES

All notices, requests, demands, deliveries and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed, postage prepaid, registered or certified mail, return receipt requested to the parties at the addresses (or at such other address for a party as shall be specified by like notice) specified on the first page of this Agreement.

WAIVER

The failure of either party at any time or times to require performances of any provision hereof shall in no manner effect the right at a later time to enforce the same. To be effective, any waiver must be contained in a written instrument signed by the party waiving compliance by the other party of the term or covenant as specified. The waiver by either party of the breach of any term or covenant contained herein, whether by conduct or otherwise, in any one or more instances, shall not be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement.

10.

GOVERNING LAW

This Agreement shall be governed by the laws of the Sate of Florida, which shall have exclusive jurisdiction over any claims or disputes arising from the subject matter contained herein without regard to any conflict of laws provision.

11.

COMPLETE AGREEMENT

This Agreement constitutes the complete and exclusive agreement between the parties hereto which supersedes all proposals, oral and written, and all other communications between the parties relating to the subject matter contained herein.

12.

SEVERABILITY

If any of the provisions of this Agreement are held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

13.

EXECUTORS, ADMINISTRATORS, SUCCESSORS AND ASSIGNS

This Agreement may not be assigned, transferred or otherwise inure to the benefit of any third person, firm or corporation by operation of law or otherwise, without the written consent by the other party hereto, except as herein specifically provided to the contrary.

-37-

14.

MODIFICATION

This Agreement may only be amended, varied or modified by a written document executed by the parties hereto.

15.

FURTHER INSTRUMENTS

The parties hereto agree to execute and deliver, or cause to be executed and delivered, such further instruments or documents and take such other action as may be required to effectively carry out the transactions contemplated herein.

16.

INDEMNIFICATION

In addition to any liability insurance to be provided the Executive, the Company will indemnify Executive (or pay, in the case of attorney fees) from any and all claims, demands, suits, actions or judgments which hereafter may by asserted, instituted or recorded by any person, firm or corporation made against Executive with respect to all expenses, losses, charges and attorney’s fees sustained or incurred by the Executive in defending any suit, action or other proceeding brought against the Executive, directly or indirectly, arising out of Executive’s employment by Company.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement this 11th day of May, 2009.

-38-

Exhibit 10.25

EMPLOYMENT AGREEMENT

AGREEMENT made as of the 11th day of May, 2009, by and between Jerry Katzman, M.D., an individual residing in Sunrise, FL (hereinafter referred to as “Executive”) and Comprehensive Care Corporation, a Delaware corporation with its principle office located at 3405 W. Dr. Martin Luther King Jr. Blvd, Suite 101, Tampa, FL 33607 (hereinafter called the “Company”).

W I T N E S S E T H

WHEREAS, the Company desires to retain the services of Executive to render his/her services to Company on the terms and conditions hereinafter set forth; and

WHEREAS, Executive is agreeable to rendering such services to the Company on the terms and conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto, intending to be legally bound, hereby agree as follows:

Employment Term, Duties and Acceptance

(a) Company hereby retains Executive as Company’s Executive Vice President of Strategic Development for a period of three (3) years, commencing on the date hereof (the “Employment Period”), subject to earlier termination as hereinafter provided, to render his/her services to Company upon the terms and conditions herein contained, in such executive capacity. In such executive capacity, Executive shall report and be responsible to the Company’s Chief Executive Officers and the Company’s Board of Directors. Notwithstanding the foregoing and notwithstanding the fact that Executive’s employment shall commence immediately, the three-year term of Executive’s employment shall be calculated from the time Executive is paid his/her full compensation on a regular basis as set forth in paragraph 2 below.

(b) Executive hereby accepts the foregoing employment and agrees to render his/her services to the Company on a full-time basis in such a manner as directed by the Company’s Chief Executive Officers as to reflect Executive’s best efforts to the end that the Company’s operations are properly managed. In furtherance of Executive performing the duties assigned to him/her under this Agreement, the Company agrees to provide Executive with a support staff reasonably required by Executive so as to enable him/her to carry out such duties.

Compensation

(a) During the first year of the term of this Agreement, Executive shall receive compensation of $390,000.00 per year. This compensation may, at the election of the Company, be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay the Company’s executives their stated compensation after the payment by the Company of its operating expenses. Executive’s compensation shall be payable in accordance with the general payroll practices of the Company as are from time to time, in effect, less such deductions or amounts as shall be required to be withheld by applicable law or regulation. On each yearly anniversary date of the execution of this Agreement (hereinafter sometimes called the “Anniversary Date,” in each yearly instance) the Board of Directors shall review the services provided by Executive to determine the amount that Executive’s salary shall be increased for the forthcoming yearly period. Such increase shall be no less than an amount equal to the percentage increase in the Consumer Price Index or such other similar index reflective of the cost of living increase in the metropolitan area of Executive’s place of residence from the beginning of the yearly period to the end of the yearly period with respect to the Consumer Price Index applicable to the said metropolitan area, times Executive’s base compensation in effect during the said yearly period. The sum resulting by way of this increase to the Executive’s base compensation shall, for the then immediately succeeding period be considered the Executive’s base compensation. The Board of Directors shall also determine on an annual (fiscal or calendar year, as the case may be) basis, the amount, if any, of bonus or incentives to be paid to Executive. Provided, however, that Executive shall receive a special bonus (“special bonus”) in an amount equal to one (1) percent of the Company’s pre-tax profits from the preceding year (as determined by the application of generally

-39-

(b) Executive shall be entitled to reasonable paid vacation time, sick leave and time to attend professional meetings comparable to that offered the executives in comparable positions.

(e) Company shall pay Executive a sign on bonus of $70,000 which, at the Company’s discretion, may be accrued, in whole or in part, until such time as the Company receives financing and/or generates sufficient revenues with which to pay the Executive.

Disability

Termination of Employment

-40-

(d) The failure of Executive’s representations herein to be materially accurate shall give the Company the right to terminate Executive’s engagement.

EXECUTIVE REPRESENTATIONS

Executive represents and warrants to the Company that:

(a) He/She has full right, power and authority to enter into this Agreement and perform the services and directions given to him/her by the Company’s Chief Executive Officer, consistent with the Executive’s position of Executive Vice President of Strategic Development, free of any further obligation to any prior employer.

(b) The Executive is not subject to the restrictions of any restrictive covenants entered into between or among the Executive and other prior employer(s).

-41-

CONFIDENTIALITY

(a) Executive agrees to execute Company’s standard form of Confidentiality Agreement as prepared by Counsel to Company and annexed hereto as Schedule A.

(b) Executive’s covenants contained herein shall survive the termination or expiration of this Agreement.

TERMINATION OF AGREEMENT

This Agreement shall, in addition to other provisions affecting termination, terminate on the occurrence of any of the following events:

(a) Cessation of the Company’s business;

(b) Dissolution of the Company; or

NOTICES

WAIVER

10.

GOVERNING LAW

11.

COMPLETE AGREEMENT

12.

SEVERABILITY

13.

EXECUTORS, ADMINISTRATORS, SUCCESSORS AND ASSIGNS

-42-

14.

MODIFICATION

This Agreement may only be amended, varied or modified by a written document executed by the parties hereto.

15.

FURTHER INSTRUMENTS

16.

INDEMNIFICATION

In addition to any liability insurance to be provided the Executive, the Company will indemnify Executive from any and all claims, demands, suits, actions or judgments which hereafter may by asserted, instituted or recorded by any person, firm or corporation made against Executive with respect to all expenses, losses, charges and attorney’s fees sustained or incurred by the Executive in defending any suit, action or other proceeding brought against the Executive, directly or indirectly, arising out of Executive’s employment by Company.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement this 11th day of May, 2009.

-43-

Exhibit 10.26

FORM OF WARRANT TO PURCHASE SERIES D PREFERRED STOCK

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

WARRANT TO PURCHASE

SHARES OF SERIES D PREFERRED STOCK

COMPREHENSIVE CARE CORPORATION

Expires May 13, 2012

Number of Shares:

Date of Issuance: May 13, 2009

FOR VALUE RECEIVED, the undersigned, Comprehensive Care Corporation, a Delaware corporation (together with its successors and assigns, the “ Issuer ”), hereby certifies that is entitled to subscribe for and purchase, during the Term (as hereinafter defined), up to shares (subject to adjustment as hereinafter provided) of the duly authorized, validly issued, fully paid and non-assessable Series D Preferred Stock of the Issuer, par value $50.00 per share (the “ Series D Preferred Stock ”), at an exercise price per share equal to the Warrant Price then in effect, subject, however, to the provisions and upon the terms and conditions hereinafter set forth.

1. Term . The term of this Warrant shall commence on May 13, 2009 and shall expire at 6:00 p.m., eastern time, on May 13, 2012 (such period being the “ Term ”).

2. Method of Exercise; Payment; Issuance of New Warrant; Transfer and Exchange .

(a) Time of Exercise . The purchase rights represented by this Warrant may be exercised in whole or in part during the Term beginning on the date of issuance hereof. However, this Warrant may not be exercised until the Issuer has increased its authorized capital from its current 30 million common shares.

(b) Method of Exercise . The Holder hereof may exercise this Warrant, in whole or in part, by the surrender of this Warrant (with the exercise form attached in Appendix A hereto duly executed) at the principal office of the Issuer, and by the payment to the Issuer of an amount of consideration therefore equal to the Warrant Price in effect on the date of such exercise multiplied by the number of shares of Warrant Stock with respect to which this Warrant is then being exercised, payable at such Holder’s election (i) by certified or official bank check or by wire transfer to an account designated by the Issuer, (ii) by “cashless exercise” in accordance with the provisions of subsection (c) of this Section 2, or (iii) when permitted by clause (ii), by a combination of the foregoing methods of payment selected by the Holder of this Warrant.

(c) Cashless Exercise . Notwithstanding any provisions herein to the contrary and commencing six-months following the Original Issue Date if the Per Share Market Value of one share of Series D Preferred Stock is greater than the Warrant Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may exercise this Warrant by a cashless exercise and shall receive the number of shares of Series D Preferred Stock equal to an amount (as determined below) by surrender of this Warrant at the principal office of the Issuer together with the properly endorsed Notice of Exercise in which event the Issuer shall issue to the Holder a number of shares of Series D Preferred Stock computed using the following formula:

LOGO

-44-


Where	X =	the number of shares of Series D Preferred Stock to be issued to the Holder.

	Y =	the number of shares of Series D Preferred Stock purchasable upon exercise of all of the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised.

	A =	the Warrant Price.

	B =	the Per Share Market Value of one share of Series D Preferred Stock.

An example of a cashless exercise is attached as Appendix B.

(d) Issuance of Stock Certificates . In the event of any exercise of this Warrant in accordance with and subject to the terms and conditions hereof, certificates for the shares of Warrant Stock so purchased shall be dated the date of such exercise and delivered to the Holder hereof within a reasonable time, not exceeding three (3) Trading Days after such exercise (the “ Delivery Date ”) or, at the request of the Holder, issued and delivered to the Depository Trust Company (“ DTC ”) account on the Holder’s behalf via the Deposit Withdrawal Agent Commission System (“ DWAC ”) within a reasonable time, not exceeding three (3) Trading Days after such exercise, and the Holder hereof shall be deemed for all purposes to be the holder of the shares of Warrant Stock so purchased as of the date of such exercise. Notwithstanding the foregoing to the contrary, the Issuer or its transfer agent shall only be obligated to issue and deliver the shares to the DTC on a holder’s behalf via DWAC if such exercise is in connection with a sale and the Issuer and its transfer agent are participating in DTC through the DWAC system. The Holder shall deliver this original Warrant, or an indemnification undertaking with respect to such Warrant in the case of its loss, theft or destruction, at such time that this Warrant is fully exercised. With respect to partial exercises of this Warrant, the Issuer shall keep written records for the Holder of the number of shares of Warrant Stock exercised as of each date of exercise.

(e) Transferability of Warrant . Subject to Section 2(g) hereof, this Warrant may be transferred by a Holder, in whole or in part. If transferred pursuant to this paragraph, this Warrant may be transferred on the books of the Issuer by the Holder hereof in person or by duly authorized attorney, upon surrender of this Warrant at the principal office of the Issuer, properly endorsed (by the Holder executing an assignment in the form attached hereto) and upon payment of any necessary transfer tax or other governmental charge imposed upon such transfer. This Warrant is exchangeable at the principal office of the Issuer for Warrants to purchase the same aggregate number of shares of Warrant Stock, each new Warrant to represent the right to purchase such number of shares of Warrant Stock as the Holder hereof shall designate at the time of such exchange. All Warrants issued on transfers or exchanges shall be dated the Original Issue Date and shall be identical with this Warrant except as to the number of shares of Warrant Stock issuable pursuant thereto.

(f) Continuing Rights of Holder . The Issuer will, at the time of or at any time after each exercise of this Warrant, upon the request of the Holder hereof, acknowledge in writing the extent, if any, of its continuing obligation to afford to such Holder all rights to which such Holder shall continue to be entitled after such exercise in accordance with the terms of this Warrant, provided that if any such Holder shall fail to make any such request, the failure shall not affect the continuing obligation of the Issuer to afford such rights to such Holder.

-45-

(g) Compliance with Securities Laws.

(i) The Holder of this Warrant, by acceptance hereof, acknowledges that this Warrant and the shares of Warrant Stock to be issued upon exercise hereof are being acquired solely for the Holder’s own account and not as a nominee for any other party, and for investment, and that the Holder will not offer, sell or otherwise dispose of this Warrant or any shares of Warrant Stock to be issued upon exercise hereof except pursuant to an effective registration statement, or an exemption from registration, under the Securities Act and any applicable state securities laws.

(ii) Except as provided in paragraph (iii) below, this Warrant and all certificates representing shares of Warrant Stock issued upon exercise hereof shall be stamped or imprinted with a legend in substantially the following form:

(iii) The Issuer agrees to reissue this Warrant or certificates representing any of the Warrant Stock, without the legend set forth above if at such time, prior to making any transfer of any such securities, the Holder shall give written notice to the Issuer describing the manner and terms of such transfer. Such proposed transfer will not be effected until: (a) either (i) the Issuer has received an opinion of counsel reasonably satisfactory to the Issuer, to the effect that the registration of such securities under the Securities Act is not required in connection with such proposed transfer, (ii) a registration statement under the Securities Act covering such proposed disposition has been filed by the Issuer with the Securities and Exchange Commission and has become effective under the Securities Act, (iii) the Issuer has received other evidence reasonably satisfactory to the Issuer that such registration and qualification under the Securities Act and state securities laws are not required, or (iv) the Holder provides the Issuer with reasonable assurances that such security can be sold pursuant to Rule 144 under the Securities Act; and (b) either (i) the Issuer has received an opinion of counsel reasonably satisfactory to the Issuer, to the effect that registration or qualification under the securities or “blue sky” laws of any state is not required in connection with such proposed disposition, or (ii) compliance with applicable state securities or “blue sky” laws has been effected or a valid exemption exists with respect thereto. The Issuer will respond to any such notice from a holder within three (3) Trading Days. In the case of any proposed transfer under this Section 2(g), the Issuer will use reasonable efforts to comply with any such applicable state securities or “blue sky” laws, but shall in no event be required, (x) to qualify to do business in any state where it is not then qualified, (y) to take any action that would subject it to tax or to the general service of process in any state where it is not then subject, or (z) to comply with state securities or “blue sky” laws of any state for which registration by coordination is unavailable to the Issuer. The restrictions on transfer contained in this Section 2(g) shall be in addition to, and not by way of limitation of, any other restrictions on transfer contained in any other section of this Warrant. Whenever a certificate representing the Warrant Stock is required to be issued to a the Holder without a legend, in lieu of delivering physical certificates representing the Warrant Stock, the Issuer shall cause its transfer agent to electronically transmit the Warrant Stock to the Holder by crediting the account of the Holder’s Prime Broker with DTC through its DWAC system (to the extent not inconsistent with any provisions of this Warrant).

(h) Accredited Investor Status . In no event may the Holder exercise this Warrant in whole or in part unless the Holder is an “accredited investor” as defined in Regulation D under the Securities Act.

(i) No Mandatory Redemption . This Warrant may not be called or redeemed by the Issuer without the written consent of the Holder.

-46-

3. Stock Fully Paid; Reservation and Listing of Shares; Covenants .

(a) Stock Fully Paid . The Issuer represents, warrants, covenants and agrees that all shares of Warrant Stock which may be issued upon the exercise of this Warrant or otherwise hereunder will, when issued in accordance with the terms of this Warrant, be duly authorized, validly issued, fully paid and non-assessable and free from all taxes, liens and charges created by or through the Issuer. The Issuer further covenants and agrees that during the period within which this Warrant may be exercised, the Issuer will at all times have authorized and reserved for the purpose of the issuance upon exercise of this Warrant a number of authorized but unissued shares of Series D Preferred Stock equal to at least one hundred percent (100%) of the number of shares of Series D Preferred Stock issuable upon exercise of this Warrant without regard to any limitations on exercise.

(b) Reservation . If any shares of Series D Preferred Stock required to be reserved for issuance upon exercise of this Warrant or as otherwise provided hereunder require registration or qualification with any Governmental Authority under any federal or state law before such shares may be so issued, the Issuer will in good faith use its best efforts as expeditiously as possible at its expense to cause such shares to be duly registered or qualified. If the Issuer shall list any shares of Series D Preferred Stock on any securities exchange or market it will, at its expense, list thereon, and maintain and increase when necessary such listing, of, all shares of Warrant Stock from time to time issued upon exercise of this Warrant or as otherwise provided hereunder (provided that such Warrant Stock has been registered pursuant to a registration statement under the Securities Act then in effect), and, to the extent permissible under the applicable securities exchange rules, all unissued shares of Warrant Stock which are at any time issuable hereunder, so long as any shares of Series D Preferred Stock shall be so listed. The Issuer will also so list on each securities exchange or market, and will maintain such listing of, any other securities which the Holder of this Warrant shall be entitled to receive upon the exercise of this Warrant if at the time any securities of the same class shall be listed on such securities exchange or market by the Issuer.

(c) Loss, Theft, Destruction of Warrants . Upon receipt of evidence satisfactory to the Issuer of the ownership of and the loss, theft, destruction or mutilation of any Warrant and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security satisfactory to the Issuer or, in the case of any such mutilation, upon surrender and cancellation of such Warrant, the Issuer will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Warrant, a new Warrant of like tenor and representing the right to purchase the same number of shares of Series D Preferred Stock.

(d) Payment of Taxes . The Issuer will pay any documentary stamp taxes attributable to the initial issuance of the Warrant Stock issuable upon exercise of this Warrant; provided , however , that the Issuer shall not be required to pay any tax or taxes which may be payable in respect of any transfer involved in the issuance or delivery of any certificates representing Warrant Stock in a name other than that of the Holder in respect to which such shares are issued.

4. Adjustment of Warrant Price and Number of Shares Issuable Upon Exercise . The Warrant Price and the number of shares of Warrant Stock that may be purchased upon exercise of this Warrant shall be subject to adjustment from time to time as set forth in this Section 4. Upon each adjustment of the Warrant Price, the Holder of this Warrant shall thereafter be entitled to purchase, at the Warrant Price resulting from such adjustment, the number of shares of Series D Preferred Stock obtained by multiplying the Warrant Price in effect immediately prior to such adjustment by the number of shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product thereof by the Warrant Price resulting from such adjustment.

(a) Adjustment Due to Dividends, Stock Splits, Etc . If, at any time on or after the Original Issuance Date, the number of outstanding shares of Series D Preferred Stock is increased by a (i) dividend payable in any kind of shares of capital stock of the Corporation, (ii) stock split, (iii) combination, (iv) reclassification or (v) other similar event, the Conversion Price shall be proportionately reduced by multiplying the Warrant Price by a fraction of which the numerator shall be the number of outstanding shares of Series D Preferred Stock immediately before such event and of which the denominator shall be the number of outstanding shares of Series D Preferred Stock immediately after such event, or if the number of outstanding shares of Series D Preferred Stock is decreased by a reverse stock split, combination or reclassification of shares, or other similar event, the Conversion Price shall be proportionately increased by multiplying the Warrant Price by a fraction of which the numerator shall be the number of outstanding shares of Series D Preferred Stock immediately before such event and of which the denominator shall be the number of outstanding shares of Series D Preferred Stock immediately after such event. In such event, the Issuer shall notify the Corporation’s Transfer Agent of such change on or before the effective date thereof.

-47-

(b) Adjustment Due to Merger, Consolidation, Etc . If, at any time after the Original Issuance Date, there shall be (i) any reclassification or change of the outstanding shares of Series D Preferred Stock or Common Stock, (ii) any consolidation or merger of the Corporation with any other entity (other than a merger in which the Corporation is the surviving or continuing entity and its capital stock is unchanged), (iii) any sale or transfer of all or substantially all of the assets of the Corporation, (iv) any share exchange or tender offer pursuant to which all of the outstanding shares of Series D Preferred Stock or Common Stock are effectively converted into other securities or property; or (v) any distribution of the Corporation’s assets to holders of the Series D Preferred Stock as a liquidation or partial liquidation dividend or by way of return of capital (each of (i) - (v) above being a “ Corporate Change ”), and, if such Corporate Change is not a Liquidation Event pursuant to the terms of Paragraph 5, then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Corporate Change if it had been, immediately prior to such Corporate Change, the holder of the number of shares of Warrant Stock then issuable upon exercise in full of this Warrant, and in any such case, appropriate provisions (in form and substance reasonably satisfactory to the Holder) shall be made with respect to the rights and interests of the Holder to the end that the economic value of the Warrant Stock is in no way diminished by such Corporate Change and that the provisions hereof including, without limitation, in the case of any such consolidation, merger or sale in which the successor entity or purchasing entity is not the Issuer, an immediate adjustment of the Warrant Price so that the Warrant Price immediately after the Corporate Change reflects the same relative value as compared to the value of the surviving entity’s common stock that existed immediately prior to such Corporate Change and the value of the Series D Preferred Stock immediately prior to such Corporate Change. If holders of Series D Preferred Stock are given any choice as to the securities, cash or property to be received in a Corporate Change, then the Holder shall be given the same choice as to the consideration it receives upon any exercise of this Warrant following such Corporate Change.

(c) Other Adjustments . If the Issuer takes any action affecting the Series D Preferred Stock after the date hereof that would be covered by this Section 4, but for the manner in which such action is taken or structured, and such action would in any way diminish the value of the Warrant or Warrant Stock, then the Warrant Price shall be adjusted in such manner as the Board shall in good faith determine to be equitable under the circumstances.

(d) Purchase Rights . In addition to any adjustments pursuant to subsections (a)-(d) above, if at any time the Issuer are grants, issues or sells any options, convertible securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of common stock (the “ Purchase Rights ”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the proportionate number of shares of Series D Preferred Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Series D Preferred Stock are to be determined for the grant, issue or sale of such Purchase Rights.

(e) Redemption Right . No sooner than fifteen (15) days nor later than ten (10) days prior to the consummation of a Corporate Change that constitutes a change of control, but not prior to the public announcement of such change of control, the Issuer shall deliver written notice thereof via facsimile and overnight courier to the Holder (a “ Change in Control Notice ”). At any time during the period beginning after the Holder’s receipt of a Change of Control Notice and ending ten (10) Trading Days after the consummation of such change of control, the Holder may require the Issuer to redeem all or any portion of this Warrant by delivering written notice thereof (“ Change in Control Redemption Notice ”) to the Issuer, which Change of Control Redemption Notice shall indicate the amount the Holder is electing to be redeemed. Any such redemption shall be in cash in the amount equal to the value of the remaining unexercised portion of this Warrant on the date of such consummation, which value shall be determined by use of the Black Scholes Option Pricing Model reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request and (B) an expected volatility equal to the 100-day volatility obtained from the HVT function on Bloomberg for the 100-day period ending on the date of the Change of Control Redemption Notice.

-48-

5. Notice of Adjustments . Whenever the Warrant Price or Warrant Share Number shall be adjusted pursuant to Section 4 hereof (for purposes of this Section 5, each an “ adjustment ”), the Issuer shall cause its Chief Financial Officer to prepare and execute a certificate setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated (including a description of the basis on which the Board made any determination hereunder), and the Warrant Price and Warrant Share Number after giving effect to such adjustment, and shall cause copies of such certificate to be delivered to the Holder of this Warrant promptly after each adjustment. Any dispute between the Issuer and the Holder of this Warrant with respect to the matters set forth in such certificate may at the option of the Holder of this Warrant be submitted to a national or regional accounting firm reasonably acceptable to the Issuer and the Holder, provided that the Issuer shall have ten (10) days after receipt of notice from such Holder of its selection of such firm to object thereto, in which case such Holder shall select another such firm and the Issuer shall have no such right of objection. The firm selected by the Holder of this Warrant as provided in the preceding sentence shall be instructed to deliver a written opinion as to such matters to the Issuer and such Holder within thirty (30) days after submission to it of such dispute. Such opinion shall be final and binding on the parties hereto. The costs and expenses of the initial accounting firm shall be paid equally by the Issuer and the Holder and, in the case of an objection by the Issuer, the costs and expenses of the subsequent accounting firm shall be paid in full by the Issuer.

6. Definitions . For the purposes of this Warrant, the following terms have the following meanings:

“ Additional Shares of Series D Preferred Stock ” means all shares of Series D Preferred Stock issued by the Issuer after the Original Issue Date, and all shares of Other Common, if any, issued by the Issuer after the Original Issue Date, except for those issued in a Permitted Financing.

“ Board ” shall mean the Board of Directors of the Issuer.

“ Capital Stock ” means and includes (i) any and all shares, interests, participations or other equivalents of or interests in (however designated) corporate stock, including, without limitation, shares of preferred or preference stock, (ii) all partnership interests (whether general or limited) in any Person which is a partnership, (iii) all membership interests or limited liability company interests in any limited liability company, and (iv) all equity or ownership interests in any Person of any other type.

“ Certificate of Incorporation ” means the Certificate of Incorporation of the Issuer as in effect on the Original Issue Date, and as hereafter from time to time amended, modified, supplemented or restated in accordance with the terms hereof and thereof and pursuant to applicable law.

“ Conversion Factor ” means the rate at which the Series D Preferred Stock converts into Common Stock, at the time of the issue of this warrant, the Conversion Factor is 100,000.

“ Common Stock ” means the Common Stock, $0.01 par value per share, of the Issuer and any other Capital Stock into which such stock may hereafter be changed.

“ Governmental Authority ” means any governmental, regulatory or self-regulatory entity, department, body, official, authority, commission, board, agency or instrumentality, whether federal, state or local, and whether domestic or foreign.

“ Holders ” mean the Persons who shall from time to time own any Warrant. The term “Holder” means one of the Holders.

“ Independent Appraiser ” means a nationally recognized or major regional investment banking firm or firm of independent certified public accountants of recognized standing (which may be the firm that regularly examines the financial statements of the Issuer) that is regularly engaged in the business of appraising the Capital Stock or assets of corporations or other entities as going concerns, and which is not affiliated with either the Issuer or the Holder of any Warrant.

“ Issuer ” means Comprehensive Care Corporation, a Delaware corporation, and its successors.

“ Original Issue Date ” means May 13, 2009.

-49-

“ OTC Bulletin Board ” means the over-the-counter electronic bulletin board.

“ Other Common ” means any other Capital Stock of the Issuer of any class which shall be authorized at any time after the date of this Warrant (other than Series D Preferred Stock) and which shall have the right to participate in the distribution of earnings and assets of the Issuer without limitation as to amount.

“ Outstanding Series D Preferred Stock ” means, at any given time, the aggregate amount of outstanding shares of Series D Preferred Stock, assuming full exercise, conversion or exchange (as applicable) of all options, warrants and other Securities which are convertible into or exercisable or exchangeable for, and any right to subscribe for, shares of Series D Preferred Stock that are outstanding at such time.

“ Person ” means an individual, corporation, limited liability company, partnership, joint stock company, trust, unincorporated organization, joint venture, Governmental Authority or other entity of whatever nature.

“ Per Share Market Value ” means on any particular date the per share market price of the Common Stock multiplied by the Conversion Factor where the per share market price of the Common Stock means, (a) the last closing bid price per share of the Common Stock on such date on the OTC Bulletin Board or another registered national stock exchange on which the Common Stock is then listed, or if there is no such price on such date, then the closing bid price on such exchange or quotation system on the date nearest preceding such date, or (b) if the Common Stock is not listed then on the OTC Bulletin Board or any registered national stock exchange, the last closing bid price for a share of Common Stock in the over-the-counter market, as reported by the OTC Bulletin Board or in the National Quotation Bureau Incorporated or similar organization or agency succeeding to its functions of reporting prices) at the close of business on such date, or (c) if the Common Stock is not then reported by the OTC Bulletin Board or the National Quotation Bureau Incorporated (or similar organization or agency succeeding to its functions of reporting prices), then the “Pink Sheet” quotes for the applicable Trading Days preceding such date of determination, or (d) if the Common Stock is not then publicly traded the fair market value of a share of Common Stock as determined by an Independent Appraiser selected in good faith by the Holder; provided , however , that the Issuer, after receipt of the determination by such Independent Appraiser, shall have the right to select an additional Independent Appraiser, in which case, the fair market value shall be equal to the average of the determinations by each such Independent Appraiser; and provided , further that all determinations of the Per Share Market Value shall be appropriately adjusted for any stock dividends, stock splits or other similar transactions during such period. The determination of fair market value by an Independent Appraiser shall be based upon the fair market value of the Issuer determined on a going concern basis as between a willing buyer and a willing seller and taking into account all relevant factors determinative of value, and the determination of the additional Independent Appraiser, if any, or of the Independent Appraisers otherwise shall be final and binding on all parties. In determining the fair market value of any shares of Series D Preferred Stock or Common Stock, no consideration shall be given to any restrictions on transfer of the Series D Preferred Stock or Common Stock imposed by agreement or by federal or state securities laws, or to the existence or absence of, or any limitations on, voting rights.

“ Securities ” means any debt or equity securities of the Issuer, whether now or hereafter authorized, any instrument convertible into or exchangeable for Securities or a Security, and any option, warrant or other right to purchase or acquire any Security. “Security” means one of the Securities.

“ Securities Act ” means the Securities Act of 1933, as amended, or any similar federal statute then in effect.

“ Series D Preferred Stock ” means the Series D Preferred Stock, $50.00 par value per share, of the Issuer and any other Capital Stock into which such stock may hereafter be changed.

-50-

“ Subsidiary ” means any corporation at least 50% of whose outstanding Voting Stock shall at the time be owned directly or indirectly by the Issuer or by one or more of its Subsidiaries, or by the Issuer and one or more of its Subsidiaries.

“ Term ” has the meaning specified in Section 1 hereof.

“ Trading Day ” means (a) a day on which the Common Stock is traded on the OTC Bulletin Board, or (b) if the Common Stock is not traded on the OTC Bulletin Board, a day on which the Common Stock is quoted in the over-the-counter market as reported by the National Quotation Bureau Incorporated (or any similar organization or agency succeeding its functions of reporting prices); provided , however , that in the event that the Common Stock is not listed or quoted as set forth in (a) or (b) hereof, then Trading Day shall mean any day except Saturday, Sunday and any day which shall be a legal holiday or a day on which banking institutions in the State of New York are authorized or required by law or other government action to close.

“ Voting Stock ” means, as applied to the Capital Stock of any corporation, Capital Stock of any class or classes (however designated) having ordinary voting power for the election of a majority of the members of the Board of Directors (or other governing body) of such corporation, other than Capital Stock having such power only by reason of the happening of a contingency.

“ Warrants ” means the Warrants issued pursuant to this Warrant, without limitation, and any other warrants of like tenor issued in substitution or exchange for any thereof pursuant to the provisions of Section 2(c), 2(d) or 2(e) hereof or of any of such other Warrants.

“ Warrant Price ” initially means $25,000.00 (TWENTY FIVE THOUSAND DOLLARS), as such price may be adjusted from time to time as shall result from the adjustments specified in this Warrant, including Section 4 hereto.

“ Warrant Share Number ” means at any time the aggregate number of shares of Warrant Stock which may at such time be purchased upon exercise of this Warrant, after giving effect to all prior adjustments and increases to such number made or required to be made under the terms hereof.

“ Warrant Stock ” means Series D Preferred Stock issuable upon exercise of any Warrant or Warrants or otherwise issuable pursuant to any Warrant or Warrants.

7. Other Notices . In case at any time:

(a)

the Issuer shall make any distributions to the holders of Series D Preferred Stock; or

(b)

the Issuer shall authorize the granting to all holders of its Series D Preferred Stock of rights to subscribe for or purchase any shares of Capital Stock of any class or other rights; or

(c)

there shall be any reclassification of the Capital Stock of the Issuer; or

(d)

there shall be any capital reorganization by the Issuer; or

(e)

there shall be any (i) consolidation or merger involving the Issuer or (ii) sale, transfer or other disposition of all or substantially all of the Issuer’s property, assets or business (except a merger or other reorganization in which the Issuer shall be the surviving corporation and its shares of Capital Stock shall continue to be outstanding and unchanged and except a consolidation, merger, sale, transfer or other disposition involving a wholly-owned subsidiary); or

(f)

there shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Issuer or any partial liquidation of the Issuer or distribution to holders of Series D Preferred Stock;

then, in each of such cases, the Issuer shall give written notice to the Holder of the date on which (i) the books of the Issuer shall close or a record shall be taken for such dividend, distribution or subscription rights or (ii) such

-51-

reorganization, reclassification, consolidation, merger, disposition, dissolution, liquidation or winding-up, as the case may be, shall take place. Such notice also shall specify the date as of which the holders of Series D Preferred Stock of record shall participate in such dividend, distribution or subscription rights, or shall be entitled to exchange their certificates for Series D Preferred Stock for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, disposition, dissolution, liquidation or winding-up, as the case may be. Such notice shall be given at least twenty (20) days prior to the action in question and not less than ten (10) days prior to the record date or the date on which the Issuer’s transfer books are closed in respect thereto. This Warrant entitles the Holder to receive copies of all financial and other information distributed or required to be distributed to the holders of the Series D Preferred Stock.

8. Amendment and Waiver . Any term, covenant, agreement or condition in this Warrant may be amended, or compliance therewith may be waived (either generally or in a particular instance and either retroactively or prospectively), by a written instrument or written instruments executed by the Issuer and the Holder; provided , however , that no such amendment or waiver shall reduce the Warrant Share Number, increase the Warrant Price, shorten the period during which this Warrant may be exercised or modify any provision of this Section 8 without the consent of the Holder of this Warrant. No consideration shall be offered or paid to any person to amend or consent to a waiver or modification of any provision of this Warrant unless the same consideration is also offered to all holders of the Warrants.

9. Governing Law; Jurisdiction . This Warrant shall be governed by and construed in accordance with the internal laws of the State of Florida, without giving effect to any of the conflicts of law principles which would result in the application of the substantive law of another jurisdiction. This Warrant shall not be interpreted or construed with any presumption against the party causing this Warrant to be drafted. The Issuer and the Holder agree that venue for any dispute arising under this Warrant will lie exclusively in the state or federal courts located in Hillsborough County, Florida, and the parties irrevocably waive any right to raise forum non conveniens or any other argument that Florida is not the proper venue. The Issuer and the Holder irrevocably consent to personal jurisdiction in the state and federal courts of the state of Florida. The Issuer and the Holder consent to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 9 shall affect or limit any right to serve process in any other manner permitted by law. The Issuer agrees to pay all costs and expenses of enforcement of this Warrant, including, without limitation, reasonable attorneys’ fees and expenses. The parties hereby waive all rights to a trial by jury.

10. Notices . All notices, requests, consents or other communications required or permitted hereunder shall be in writing and shall be hand delivered or mailed first class postage prepaid, registered or certified mail, to the following address:

In the case of the Issuer:

John Hill, Co-Chief Executive Officer

Comprehensive Care Corporation

3405 W. Martin Luther King Jr. Blvd, Suite 101

Tampa, FL 33607

In the case of the Holder:

Such notices and other communications shall, for all purposes of this Agreement, be treated as being effective upon being delivered personally or, if sent by mail, five days after the same has been deposited in a regularly maintained receptacle for the deposit of United States mail, addressed as set forth above, and postage prepaid. Any party hereto may from time to time change its address for notices by giving written notice of such changed address to the other party hereto.

-52-

11. Remedies . The Issuer stipulates that the remedies at law of the Holder of this Warrant in the event of any default or threatened default by the Issuer in the performance of or compliance with any of the terms of this Warrant are not and will not be adequate and that, to the fullest extent permitted by law, such terms may be specifically enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of any of the terms hereof or otherwise.

12. Successors and Assigns . This Warrant and the rights evidenced hereby shall inure to the benefit of and be binding upon the successors and assigns of the Issuer, the Holder hereof and (to the extent provided herein) the Holders of Warrant Stock issued pursuant hereto, and shall be enforceable by any such Holder or Holder of Warrant Stock.

13. Modification and Severability . If, in any action before any court or agency legally empowered to enforce any provision contained herein, any provision hereof is found to be unenforceable, then such provision shall be deemed modified to the extent necessary to make it enforceable by such court or agency. If any such provision is not enforceable as set forth in the preceding sentence, the unenforceability of such provision shall not affect the other provisions of this Warrant, but this Warrant shall be construed as if such unenforceable provision had never been contained herein.

14. Headings . The headings of the Sections of this Warrant are for convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

-53-

IN WITNESS WHEREOF, the Issuer has executed this Warrant as of the day and year first above written.


COMPREHENSIVE CARE CORPORATION

By:

-54-

APPENDIX A

WARRANT EXERCISE FORM

COMPREHENSIVE CARE CORPORATION

The undersigned , pursuant to the provisions of the within Warrant, hereby elects to purchase shares of Series D Preferred Stock of Comprehensive Care Corporation covered by the within Warrant.


Dated:						Signature

						Address

Number of shares of Series D Preferred Stock beneficially owned or deemed beneficially owned by the Holder on the date of Exercise:

The undersigned is an “accredited investor” as defined in Regulation D under the Securities Act of 1933, as amended.

The undersigned intends that payment of the Warrant Price shall be made as (check one):

Cash Exercise

Cashless Exercise

If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ by certified or official bank check (or via wire transfer) to the Issuer in accordance with the terms of the Warrant.

If the Holder has elected a Cashless Exercise, a certificate shall be issued to the Holder for the number of shares equal to the whole number portion of the product of the calculation set forth below, which is . The Company shall pay a cash adjustment in respect of the fractional portion of the product of the calculation set forth below in an amount equal to the product of the fractional portion of such product and the Per Share Market Value on the date of exercise, which product is .


Where:

The number of shares of Series D Preferred Stock to be issued to the Holder (“X”).

The number of shares of Series D Preferred Stock purchasable upon exercise of all of the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised (“Y”).

The Warrant Price (“A”).

The Per Share Market Value of one share of Series D Preferred Stock (“B”).

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

ASSIGNMENT

FOR VALUE RECEIVED, hereby sells, assigns and transfers unto the within Warrant and all rights evidenced thereby and does irrevocably constitute and appoint , attorney, to transfer the said Warrant on the books of the within named corporation.


Dated:						Signature

						Address

PARTIAL ASSIGNMENT

FOR VALUE RECEIVED, hereby sells, assigns and transfers unto the right to purchase shares of Warrant Stock evidenced by the within Warrant together with all rights therein, and does irrevocably constitute and appoint , attorney, to transfer that part of the said Warrant on the books of the within named corporation.


Dated:						Signature

						Address

FOR USE BY THE ISSUER ONLY:

This Warrant No. W- canceled (or transferred or exchanged) this day of , , shares of Series D Preferred Stock issued therefore in the name of , Warrant No. W- issued for shares of Series D Preferred Stock in the name of .

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

APPENDIX B

CASHLESS CONVERSION EXAMPLE


Example:		One year following issue of Warrant, Holder of 10 warrants wishes to exercise all the warrants on a cashless basis pursuant to Section 2 (c). On that date, CompCare’s FMV as determined by its closing share price for its Common Stock was $1.25 per share (in accordance with the definition of Per Share Market Value provided in Section 7).

Using the following formula:

LOGO


Where	X =	the number of shares of Series D Preferred Stock to be issued to the Holder.

	Y =	the number of shares of Series D Preferred Stock purchasable upon exercise of all of the Warrant, in this example, this will be 10.

	A =	the Warrant Price, being $25,000 per Series D share.

	B =	the Per Share Market Value of one share of Series D Preferred Stock, in this example using the definition provided in Section 7, being the share price for the Series D stock will be the share price for the Common Stock multiplied by the Conversion Factor. In this example, this will be $1.25 multiplied by 100,000 = $125,000.

Thus:

LOGO


Therefore		X = 8		Series D Shares

In this example, the Holder can request a cashless exercise of the full 10 warrants and receive 8 Series D Preferred Stock in return. Note that the Warrant will now be canceled in its entirety and be deemed fully exercised. Where the Warrant Share Number was for greater than 10 warrants, a new warrant will be issued where the new Warrant Share Number will be the existing Warrant Share Number prior to the cashless conversion less 10.

Exhibit 31.1

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, John M. Hill, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Comprehensive Care Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


		/s/ JOHN M. HILL
May 15, 2009		John M. Hill
		President and Co-Chief Executive Officer
		(Principal Executive Officer)

Exhibit 31.2

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Clark A. Marcus, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Comprehensive Care Corporation;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


		/s/ CLARK A. MARCUS
May 15, 2009		Clark A. Marcus
		Co-Chief Executive Officer
		(Principal Executive Officer)

Exhibit 31.3

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Giuseppe Crisafi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Comprehensive Care Corporation;

b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


		/s/ GIUSEPPE CRISAFI
May 15, 2009		Giuseppe Crisafi
		Chief Financial Officer
		(Principal Financial Officer)

Exhibit 32.1

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of CEO Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Comprehensive Care Corporation (the “Company”) on Form 10-Q for the quarter ending March 31, 2009 as filed with the Securities and Exchange Commission on May 15, 2009 (the “Report”), John M. Hill, as Co-Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C.§ 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ JOHN M. HILL

John M. Hill

President and Co-Chief Executive Officer

May 15, 2009

Exhibit 32.2

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of CEO Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Comprehensive Care Corporation (the “Company”) on Form 10-Q for the quarter ending March 31, 2009 as filed with the Securities and Exchange Commission on May 15, 2009 (the “Report”), Clark A. Marcus, as Co-Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C.§ 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ CLARK A. MARCUS

Clark A. Marcus

Co-Chief Executive Officer

May 15, 2009

Exhibit 32.3

COMPREHENSIVE CARE CORPORATION AND SUBSIDIARIES

Certification of CFO Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of Comprehensive Care Corporation (the “Company”) on Form 10-Q for the quarter ending March 31, 2009 as filed with the Securities and Exchange Commission on May 15, 2009 (the “Report”), Giuseppe Crisafi, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ GIUSEPPE CRISAFI

Giuseppe Crisafi

Chief Financial Officer

May 15, 2009

Large Accelerated Filer

Accelerated Filer

Non-Accelerated Filer

Smaller reporting company